[{"medicine_name":"bcg vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against tuberculosis","combined_with":null,"status":"Added","atc_classification":"L03AX03","source":"who.int"},{"medicine_name":"japanese encephalitis vaccine","eml_section":"Recommendations for certain regions","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BA02","source":"who.int"},{"medicine_name":"japanese encephalitis vaccine","eml_section":"Recommendations for certain regions","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BA03","source":"who.int"},{"medicine_name":"medicines for covid-19","eml_section":"Medicines for COVID-19","formulations":"Refer to WHO living guidelines","indication":"COVID-19","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"abacavir","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Solid: 300 mg tablet (as sulfate)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AF06","source":"who.int"},{"medicine_name":"abacavir + lamivudine","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR02","source":"who.int"},{"medicine_name":"abacavir + lamivudine + lopinavir + ritonavir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"abiraterone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 250 mg; 500 mg","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"L02BX03","source":"who.int"},{"medicine_name":"acetazolamide","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Oral > Solid: 250 mg","indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"S01EC01","source":"who.int"},{"medicine_name":"acetic acid","eml_section":"Ear, nose and throat medicines [c]","formulations":"Local > Otological > drops: 2% in alcohol","indication":"Infectious diseases of external ear","combined_with":null,"status":"Added","atc_classification":"S02AA10","source":"who.int"},{"medicine_name":"acetylcysteine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule\nOral > Liquid: 10%; 20%","indication":"Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs","combined_with":null,"status":"Added","atc_classification":"V03AB23","source":"who.int"},{"medicine_name":"acetylcysteine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule\nOral > Liquid: 10%; 20%","indication":"Acute or subacute hepatic failure","combined_with":null,"status":"Removed","atc_classification":"V03AB23","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Antimigraine medicines > For treatment of acute attack","formulations":"Oral > Solid: 300 to 500 mg","indication":"Migraine","combined_with":null,"status":"Added","atc_classification":"N02BA01","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Anti-platelet medicines","formulations":"Oral > Solid: 100 mg","indication":"Acute myocardial infarction","combined_with":null,"status":"Added","atc_classification":"B01AC06","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Anti-platelet medicines","formulations":"Oral > Solid: 100 mg","indication":"Cerebral ischaemic stroke","combined_with":null,"status":"Added","atc_classification":"B01AC06","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Medicines for juvenile joint diseases","formulations":"Oral > Solid: 100 to 500 mg\nLocal > Rectal > Suppository: 50 to 150 mg","indication":"Acute rheumatic fever without mention of heart involvement","combined_with":null,"status":"Added","atc_classification":"N02BA01","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Medicines for juvenile joint diseases","formulations":"Oral > Solid: 100 to 500 mg\nLocal > Rectal > Suppository: 50 to 150 mg","indication":"Mucocutaneous lymph node syndrome","combined_with":null,"status":"Added","atc_classification":"N02BA01","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Medicines for juvenile joint diseases","formulations":"Oral > Solid: 100 to 500 mg\nLocal > Rectal > Suppository: 50 to 150 mg","indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"N02BA01","source":"who.int"},{"medicine_name":"acetylsalicylic acid","eml_section":"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","formulations":"Oral > Solid: 100 to 500 mg\nLocal > Rectal > Suppository: 50 to 150 mg","indication":"Pain","combined_with":null,"status":"Added","atc_classification":"N02BA01","source":"who.int"},{"medicine_name":"aciclovir","eml_section":"Antiherpes medicines","formulations":"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)\nOral > Liquid: 200 mg per 5 mL\nOral > Solid: 200 mg tablet","indication":"Zoster","combined_with":null,"status":"Added","atc_classification":"J05AB01","source":"who.int"},{"medicine_name":"aciclovir","eml_section":"Antiherpes medicines","formulations":"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)\nOral > Liquid: 200 mg per 5 mL\nOral > Solid: 200 mg tablet","indication":"Varicella","combined_with":null,"status":"Added","atc_classification":"J05AB01","source":"who.int"},{"medicine_name":"aciclovir","eml_section":"Antiherpes medicines","formulations":"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)\nOral > Liquid: 200 mg per 5 mL\nOral > Solid: 200 mg tablet","indication":"Herpes simplex infections","combined_with":null,"status":"Added","atc_classification":"J05AB01","source":"who.int"},{"medicine_name":"aciclovir","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 3% w\/w","indication":"Herpes simplex keratitis","combined_with":null,"status":"Added","atc_classification":"S01AD03","source":"who.int"},{"medicine_name":"aclidinium","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"activated charcoal","eml_section":"Antidotes and other substances used in poisonings > Non-specific","formulations":"Oral > Other: powder","indication":"Unspecified injury, poisoning or certain other consequences of external causes","combined_with":null,"status":"Added","atc_classification":"A07BA01","source":"who.int"},{"medicine_name":"adalimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","indication":"Axial spondyloarthritis","combined_with":null,"status":"Added","atc_classification":"L04AB04","source":"who.int"},{"medicine_name":"adalimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"L04AB04","source":"who.int"},{"medicine_name":"adalimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"L04AB04","source":"who.int"},{"medicine_name":"adalimumab","eml_section":"Medicines for juvenile joint diseases","formulations":"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"L04AB04","source":"who.int"},{"medicine_name":"afatinib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Echinococcosis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Ascariasis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Enterobiasis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Trichuriasis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Hookworm diseases","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)\nOral > Solid > tablet: 400 mg (chewable, scored))","indication":"Cysticercosis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Cysticidal medicines","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)","indication":"Other specified echinococcosis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Cysticidal medicines","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)","indication":"Cysticercosis of central nervous system","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"albendazole","eml_section":"Antifilarials","formulations":"Oral > Solid > tablet: 400 mg (chewable, scored)","indication":"Filariasis","combined_with":null,"status":"Added","atc_classification":"P02CA03","source":"who.int"},{"medicine_name":"alcohol based hand rub","eml_section":"Disinfectants","formulations":"Local > Topical > Solution: 80% v\/v ethanol; 75% v\/v isopropyl alcohol","indication":"Denatured alcohol","combined_with":null,"status":"Added","atc_classification":"D08AX08","source":"who.int"},{"medicine_name":"alcuronium","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 5 mg per  mL in 2 mL ampoule (alcuronium chloride)","indication":"Muscle relaxants","combined_with":null,"status":"Removed","atc_classification":"M03AA01","source":"who.int"},{"medicine_name":"all-trans retinoic acid","eml_section":"Targeted therapies","formulations":"Oral > Solid: 10 mg capsule","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01XF01","source":"who.int"},{"medicine_name":"allopurinol","eml_section":"Medicines used to treat gout","formulations":"Oral > Solid: 100 mg","indication":"Gout","combined_with":null,"status":"Added","atc_classification":"M04AA01","source":"who.int"},{"medicine_name":"allopurinol","eml_section":"Supportive medicines","formulations":"Oral > Solid: 100 mg; 300 mg","indication":"Tumour lysis syndrome","combined_with":null,"status":"Added","atc_classification":"M04AA01","source":"who.int"},{"medicine_name":"alteplase","eml_section":"Thrombolytic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection","indication":"Cerebral ischaemic stroke","combined_with":null,"status":"Added","atc_classification":"B01AD02","source":"who.int"},{"medicine_name":"amidotrizoate","eml_section":"Diagnostic agents > Radiocontrast media","formulations":"Parenteral > General injections > unspecified: 140 to 420 mg iodine per  mL in 20 mL ampoule (as sodium or meglumine salt)","indication":"Amidotrizoate","combined_with":null,"status":"Added","atc_classification":"V08AA01","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","indication":"Acute pyelonephritis (severe)","combined_with":"cefotaxime","status":"Added","atc_classification":"J01GB06","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","indication":"Acute pyelonephritis (severe)","combined_with":"ceftriaxone","status":"Added","atc_classification":"J01GB06","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","indication":"Sepsis without septic shock","combined_with":"cloxacillin","status":"Added","atc_classification":"J01GB06","source":"who.int"},{"medicine_name":"amikacin","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01GB06","source":"who.int"},{"medicine_name":"amiloride","eml_section":"Diuretics","formulations":"Oral > Solid: 5 mg (hydrochloride)","indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"C03DB01","source":"who.int"},{"medicine_name":"amiloride","eml_section":"Diuretics","formulations":"Oral > Solid: 5 mg (hydrochloride)","indication":"Ascites","combined_with":null,"status":"Added","atc_classification":"C03DB01","source":"who.int"},{"medicine_name":"amiodarone","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 3 ampoule (hydrochloride)\nOral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)","indication":"Cardiac arrhythmia","combined_with":null,"status":"Added","atc_classification":"C01BD01","source":"who.int"},{"medicine_name":"amitriptyline","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Solid: 25 mg; 10 mg; 75 mg","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"N06AA09","source":"who.int"},{"medicine_name":"amlodipine","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 5 mg (as maleate, mesylate or besylate)","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C08CA01","source":"who.int"},{"medicine_name":"amodiaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BA06","source":"who.int"},{"medicine_name":"amodiaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BA06","source":"who.int"},{"medicine_name":"amodiaquine + sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package","indication":"Malaria","combined_with":null,"status":"Added","atc_classification":"P01BA06","source":"who.int"},{"medicine_name":"amodiaquine + sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package","indication":"Malaria","combined_with":null,"status":"Added","atc_classification":"P01BD51","source":"who.int"},{"medicine_name":"amoxicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet\nOral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid\nOral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)\nParenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","indication":"Sepsis without septic shock","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA04","source":"who.int"},{"medicine_name":"amoxicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet\nOral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid\nOral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)\nParenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","indication":"Chronic obstructive pulmonary disease with acute exacerbation","combined_with":null,"status":"Added","atc_classification":"J01CA04","source":"who.int"},{"medicine_name":"amoxicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet\nOral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid\nOral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)\nParenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CA04","source":"who.int"},{"medicine_name":"amoxicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet\nOral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid\nOral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)\nParenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","indication":"Infectious cystitis","combined_with":null,"status":"Removed","atc_classification":"J01CA04","source":"who.int"},{"medicine_name":"amoxicillin + clavulanic acid","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid\nOral > Solid: 500 mg + 125 mg tablet\nOral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","indication":"Chronic obstructive pulmonary disease with acute exacerbation","combined_with":null,"status":"Added","atc_classification":"J01CR02","source":"who.int"},{"medicine_name":"amoxicillin + clavulanic acid","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid\nOral > Solid: 500 mg + 125 mg tablet\nOral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","indication":"Infectious cystitis","combined_with":null,"status":"Added","atc_classification":"J01CR02","source":"who.int"},{"medicine_name":"amoxicillin + clavulanic acid","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid\nOral > Solid: 500 mg + 125 mg tablet\nOral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)\nOral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CR02","source":"who.int"},{"medicine_name":"amoxicillin + clavulanic acid","eml_section":"Antituberculosis medicines","formulations":"Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid\nOral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01CR02","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Blastomycosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Aspergillosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Cryptococcosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Candidosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Coccidioidomycosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Histoplasmosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Sporotrichosis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"amphotericin b","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","indication":"Visceral leishmaniasis","combined_with":null,"status":"Added","atc_classification":"J02AA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Acute malnutrition in infants, children or adolescents (complicated) [children]","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Peritonitis (mild-moderate)","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Peritonitis (severe)","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Peritoneal abscess (mild-moderate)","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Peritoneal abscess (severe)","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Sepsis without septic shock","combined_with":"gentamicin","status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Bacterial meningitis","combined_with":null,"status":"Added","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"ampicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection\nOral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension\nOral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CA01","source":"who.int"},{"medicine_name":"anastrozole","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 1 mg tablet","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L02BG03","source":"who.int"},{"medicine_name":"anastrozole","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 1 mg tablet","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L02BG03","source":"who.int"},{"medicine_name":"anidulafungin","eml_section":"Antifungal medicines","formulations":null,"indication":"Systemic or invasive candidosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ansuvimab","eml_section":"Medicines for Ebola virus disease","formulations":"Parenteral > General injections > IV: 400 mg powder for injection","indication":"Ebola virus disease","combined_with":null,"status":"Added","atc_classification":"J06BD04","source":"who.int"},{"medicine_name":"anti-d immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IV: 250 \u00b5g in single-dose vial\nParenteral > General injections > IM: 250 \u00b5g in single-dose vial","indication":"Maternal care for red cell antibodies","combined_with":null,"status":"Added","atc_classification":"J06BB01","source":"who.int"},{"medicine_name":"anti-d immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IV: 250 \u00b5g in single-dose vial\nParenteral > General injections > IM: 250 \u00b5g in single-dose vial","indication":"Rh incompatibility reaction","combined_with":null,"status":"Added","atc_classification":"J06BB01","source":"who.int"},{"medicine_name":"anti-rabies immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IM: 150 IU per  mL in vial\nParenteral > Locoregional injections > Other: 150 IU per  mL in vial","indication":"Rabies","combined_with":null,"status":"Added","atc_classification":"J06BB05","source":"who.int"},{"medicine_name":"anti-rabies virus monoclonal antibodies","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > Locoregional injections > Intradermal: 40 IU per  mL in 1.25 mL vial (human); 40 IU per  mL in 2.5 mL vial (human); 100 IU per  mL in 2.5 mL vial (human); 300 IU per  mL in 10 mL vial (murine); 600 IU per  mL in 1 mL vial (murine); 600 IU per  mL in 2.5 mL vial (murine); 600 IU per  mL in 5 mL vial (murine)","indication":"Rabies","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"anti-tetanus immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IM: 500 IU in vial","indication":"Tetanus","combined_with":null,"status":"Added","atc_classification":"J06BB02","source":"who.int"},{"medicine_name":"antirabies hyperimmune serum","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule","indication":"Rabies","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"antivenom immunoglobulin","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > General injections > IV: ","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"antivenom sera","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > General injections > IV: ","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"apixaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"apixaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Other specified atrial fibrillation","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"aprepitant","eml_section":"Antiemetic medicines","formulations":"Oral > Liquid: 125 mg powder for oral suspension (in sachet)\nOral > Solid: 80 mg; 125 mg; 165 mg","indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"A04AD12","source":"who.int"},{"medicine_name":"arsenic trioxide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg per  mL concentrate for solution for infusion; 2 mg per  mL concentrate for solution for infusion","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01XX27","source":"who.int"},{"medicine_name":"artemether","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BE02","source":"who.int"},{"medicine_name":"artemether","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BE02","source":"who.int"},{"medicine_name":"artemether + lumefantrine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BF01","source":"who.int"},{"medicine_name":"artemether + lumefantrine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BF01","source":"who.int"},{"medicine_name":"artesunate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution\nOral > Solid: 50 mg tablet\nLocal > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BE03","source":"who.int"},{"medicine_name":"artesunate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution\nOral > Solid: 50 mg tablet\nLocal > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BE03","source":"who.int"},{"medicine_name":"artesunate + amodiaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BF03","source":"who.int"},{"medicine_name":"artesunate + amodiaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BF03","source":"who.int"},{"medicine_name":"artesunate + mefloquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BF02","source":"who.int"},{"medicine_name":"artesunate + mefloquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BF02","source":"who.int"},{"medicine_name":"artesunate + pyronaridine tetraphosphate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BF06","source":"who.int"},{"medicine_name":"artesunate + pyronaridine tetraphosphate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BF06","source":"who.int"},{"medicine_name":"ascorbic acid","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 50 mg","indication":"Scurvy","combined_with":null,"status":"Added","atc_classification":"A11GA01","source":"who.int"},{"medicine_name":"asparaginase","eml_section":"Cytotoxic medicines","formulations":"Powder for injection: 10 000 IU in vial.\nParenteral > General injections > unspecified: 10000 IU in vial powder for injection","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01XX02","source":"who.int"},{"medicine_name":"asparaginase","eml_section":"Cytotoxic medicines","formulations":"Powder for injection: 10 000 IU in vial.\nParenteral > General injections > unspecified: 10000 IU in vial powder for injection","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01XX02","source":"who.int"},{"medicine_name":"atazanavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AE08","source":"who.int"},{"medicine_name":"atazanavir + ritonavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR23","source":"who.int"},{"medicine_name":"atenolol","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 50 mg; 100 mg","indication":"Angina pectoris","combined_with":null,"status":"Removed","atc_classification":"C07AB03","source":"who.int"},{"medicine_name":"atenolol","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 50 mg; 100 mg\n","indication":"Essential hypertension","combined_with":null,"status":"Removed","atc_classification":"C07AB03","source":"who.int"},{"medicine_name":"atenolol","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 50 mg; 100 mg\n","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"atezolizumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Removed","atc_classification":"L01XC18","source":"who.int"},{"medicine_name":"atoltivimab + maftivimab + odesivimab","eml_section":"Medicines for Ebola virus disease","formulations":"Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial","indication":"Ebola virus disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"atorvastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Mixed hyperlipidaemia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"atorvastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Coronary atherosclerosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"atracurium","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 10 mg per  mL (besylate)","indication":"Muscle relaxants","combined_with":null,"status":"Added","atc_classification":"M03AC04","source":"who.int"},{"medicine_name":"atropine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)","indication":"Exposure to or harmful effects of undetermined intent of pesticides","combined_with":null,"status":"Added","atc_classification":"A03BA01","source":"who.int"},{"medicine_name":"atropine","eml_section":"Preoperative medication and sedation for short-term procedures","formulations":"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)","indication":"Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics","combined_with":null,"status":"Added","atc_classification":"A03BA01","source":"who.int"},{"medicine_name":"atropine","eml_section":"Diagnostic agents > Ophthalmic medicines","formulations":null,"indication":"Cycloplegic drug","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"atropine","eml_section":"Ophthalmological preparations > Mydriatics","formulations":"Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)","indication":"Anterior uveitis","combined_with":null,"status":"Added","atc_classification":"S01FA01","source":"who.int"},{"medicine_name":"axicabtagene ciloleucel","eml_section":"Antineoplastics and supportive medicines","formulations":"Cell suspension for infusion: 2 \u00d7 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Removed","atc_classification":"L01XL03","source":"who.int"},{"medicine_name":"azacitidine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 100 mg in vial powder for injection","indication":"Myeloid leukaemia","combined_with":null,"status":"Removed","atc_classification":"L01BC07","source":"who.int"},{"medicine_name":"azathioprine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 50 mg","indication":"Rheumatoid arthritis, serology unspecified","combined_with":null,"status":"Added","atc_classification":"L04AX01","source":"who.int"},{"medicine_name":"azathioprine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 50 mg","indication":"Psoriatic arthritis","combined_with":null,"status":"Added","atc_classification":"L04AX01","source":"who.int"},{"medicine_name":"azathioprine","eml_section":"Immunomodulators for non-malignant disease","formulations":"Oral > Solid: 50 mg\nParenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)\nOral > Liquid: 10 mg per  mL\nOral > Solid > tablet: 50 mg (scored); 25 mg","indication":"Relapsing-remitting multiple sclerosis","combined_with":null,"status":"Removed","atc_classification":"L04AX01","source":"who.int"},{"medicine_name":"azathioprine","eml_section":"Immunomodulators for non-malignant disease","formulations":"Oral > Solid: 50 mg\nParenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)\nOral > Liquid: 10 mg per  mL\nOral > Solid > tablet: 50 mg (scored); 25 mg","indication":"Failure or rejection of transplanted organs or tissues","combined_with":null,"status":"Added","atc_classification":"L04AX01","source":"who.int"},{"medicine_name":"azithromycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 1.5% eye drops","indication":"Trachoma","combined_with":null,"status":"Added","atc_classification":"S01AA26","source":"who.int"},{"medicine_name":"azithromycin","eml_section":"Watch group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL oral liquid\nOral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule","indication":"Gonococcal infection","combined_with":"ceftriaxone","status":"Added","atc_classification":"J01FA10","source":"who.int"},{"medicine_name":"azithromycin","eml_section":"Watch group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL oral liquid\nOral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule","indication":"Gonococcal infection","combined_with":"cefixime","status":"Added","atc_classification":"J01FA10","source":"who.int"},{"medicine_name":"aztreonam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01DF01","source":"who.int"},{"medicine_name":"barium sulfate","eml_section":"Diagnostic agents > Radiocontrast media","formulations":"Oral > Liquid: Aqueous suspension","indication":"Barium sulfate with suspending agents","combined_with":null,"status":"Added","atc_classification":"V08BA01","source":"who.int"},{"medicine_name":"beclometasone","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"\nRespiratory > Inhalation > aerosol: 50 \u00b5g per  dose (dipropionate); 250 \u00b5g per  dose (dipropionatae)","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"beclometasone","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"\nRespiratory > Inhalation > aerosol: 50 \u00b5g per  dose (dipropionate); 250 \u00b5g per  dose (dipropionatae)","indication":"Asthma","combined_with":null,"status":"Removed","atc_classification":"R03BA01","source":"who.int"},{"medicine_name":"beclometasone + formoterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bedaquiline","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 100 mg tablet; 20 mg tablet","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK05","source":"who.int"},{"medicine_name":"bendamustine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA09","source":"who.int"},{"medicine_name":"bendamustine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA09","source":"who.int"},{"medicine_name":"benzathine benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","indication":"Congenital syphilis [children]","combined_with":null,"status":"Added","atc_classification":"J01CE08","source":"who.int"},{"medicine_name":"benzathine benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","indication":"Syphilis","combined_with":null,"status":"Added","atc_classification":"J01CE08","source":"who.int"},{"medicine_name":"benzathine benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CE08","source":"who.int"},{"medicine_name":"benznidazole","eml_section":"American trypanosomiasis","formulations":"Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg","indication":"Chagas disease","combined_with":null,"status":"Added","atc_classification":"P01CA02","source":"who.int"},{"medicine_name":"benzoic acid + salicylic acid","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Cream: 6% + 3%\nLocal > Topical > Ointment: 6% + 3%","indication":"Fungal infection of the skin","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"benzoyl peroxide","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Cream: 5%\nLocal > Topical > Lotion: 5%","indication":"Acne","combined_with":null,"status":"Added","atc_classification":"D10AE01","source":"who.int"},{"medicine_name":"benzyl benzoate","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 25%","indication":"Pthiriasis","combined_with":null,"status":"Added","atc_classification":"P03AX01","source":"who.int"},{"medicine_name":"benzyl benzoate","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 25%","indication":"Pediculosis corporis","combined_with":null,"status":"Added","atc_classification":"P03AX01","source":"who.int"},{"medicine_name":"benzyl benzoate","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 25%","indication":"Pediculosis capitis","combined_with":null,"status":"Added","atc_classification":"P03AX01","source":"who.int"},{"medicine_name":"benzyl benzoate","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 25%","indication":"Scabies","combined_with":null,"status":"Added","atc_classification":"P03AX01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","combined_with":"gentamicin","status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Congenital syphilis [children]","combined_with":null,"status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Syphilis","combined_with":null,"status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Acute malnutrition in infants, children or adolescents (complicated) [children]","combined_with":"gentamicin","status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Sepsis without septic shock","combined_with":"gentamicin","status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Bacterial meningitis","combined_with":null,"status":"Added","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)\nParenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CE01","source":"who.int"},{"medicine_name":"betamethasone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 0.1% (as valerate)\nLocal > Topical > Ointment: 0.1% (as valerate)","indication":"Pruritus due to skin disorder","combined_with":null,"status":"Added","atc_classification":"D07AC01","source":"who.int"},{"medicine_name":"betamethasone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 0.1% (as valerate)\nLocal > Topical > Ointment: 0.1% (as valerate)","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"D07AC01","source":"who.int"},{"medicine_name":"betamethasone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 0.1% (as valerate)\nLocal > Topical > Ointment: 0.1% (as valerate)","indication":"Dermatitis or eczema","combined_with":null,"status":"Added","atc_classification":"D07AC01","source":"who.int"},{"medicine_name":"betamethasone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 0.1% (as valerate)\nLocal > Topical > Ointment: 0.1% (as valerate)","indication":"Lichen planus","combined_with":null,"status":"Added","atc_classification":"D07AC01","source":"who.int"},{"medicine_name":"bevacizumab","eml_section":"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","formulations":"Parenteral > Locoregional injections > Intravitreal: 25 mg per  mL","indication":"Age related macular degeneration","combined_with":null,"status":"Added","atc_classification":"S01LA08","source":"who.int"},{"medicine_name":"bicalutamide","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 50 mg","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"L02BB03","source":"who.int"},{"medicine_name":"binimetinib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"biperiden","eml_section":"Medicines for parkinsonism","formulations":"Parenteral > General injections > IV: 5 mg per  mL in 1 mL ampoule (lactate)\nOral > Solid: 2 mg tablet (hydrochloride)","indication":"Parkinson disease","combined_with":null,"status":"Added","atc_classification":"N04AA02","source":"who.int"},{"medicine_name":"bisacodyl","eml_section":"Laxatives","formulations":null,"indication":"Constipation","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bisoprolol","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 1.25 mg; 5 mg","indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"C07AB07","source":"who.int"},{"medicine_name":"bisoprolol","eml_section":"Medicines used in heart failure","formulations":"Oral > Solid: 1.25 mg; 5 mg","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C07AB07","source":"who.int"},{"medicine_name":"bisoprolol","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 1.25 mg; 5 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C07AB07","source":"who.int"},{"medicine_name":"bisoprolol","eml_section":"Antiarrhythmic medicines","formulations":"Oral > Solid: 1.25 mg; 5 mg","indication":"Cardiac arrhythmia","combined_with":null,"status":"Added","atc_classification":"C07AB07","source":"who.int"},{"medicine_name":"bleomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)\nParenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01DC01","source":"who.int"},{"medicine_name":"bleomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)\nParenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","indication":"Kaposi sarcoma of unspecified primary site","combined_with":null,"status":"Added","atc_classification":"L01DC01","source":"who.int"},{"medicine_name":"bleomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)\nParenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01DC01","source":"who.int"},{"medicine_name":"bleomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)\nParenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01DC01","source":"who.int"},{"medicine_name":"bleomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)\nParenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01DC01","source":"who.int"},{"medicine_name":"bortezomib","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L01XG01","source":"who.int"},{"medicine_name":"bromocriptine","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 2.5 mg; 5 mg","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BC01","source":"who.int"},{"medicine_name":"budesonide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Respiratory > Inhalation > aerosol: 100 \u00b5g per  dose; 200 \u00b5g per  dose","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"R03BA02","source":"who.int"},{"medicine_name":"budesonide","eml_section":"Ear, nose and throat medicines [c]","formulations":"Local > Nasal > Spray: 100 \u00b5g per  dose","indication":"Allergic rhinitis","combined_with":null,"status":"Added","atc_classification":"R01AD05","source":"who.int"},{"medicine_name":"budesonide + formoterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Respiratory > Inhalation > dry powder: 100 \u00b5g + 6 \u00b5g per dose; 200 \u00b5g + 6 \u00b5g per dose","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"R03AK07","source":"who.int"},{"medicine_name":"budesonide + salmeterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bumetanide","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bumetanide","eml_section":"Diuretics","formulations":null,"indication":"Anuria or oliguria","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bumetanide","eml_section":"Diuretics","formulations":null,"indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bupivacaine","eml_section":"Local anaesthetics","formulations":"Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution\nParenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)","indication":"Local anaesthetics","combined_with":null,"status":"Added","atc_classification":"N01BB01","source":"who.int"},{"medicine_name":"buprenorphine","eml_section":"Medicines for opioid use disorders","formulations":null,"indication":"Opioid dependence","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"bupropion","eml_section":"Medicines for nicotine use disorders","formulations":"Oral > Solid: 150 mg sustained-release (hydrochloride)","indication":"Nicotine dependence","combined_with":null,"status":"Added","atc_classification":"N06AX12","source":"who.int"},{"medicine_name":"c1 esterase inhibitor","eml_section":"Plasma-derived medicines","formulations":"Parenteral > General injections > IV: 500 IU in vial powder for injection","indication":"Hereditary angioedema","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"cabergoline","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 0.5 mg","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BC06","source":"who.int"},{"medicine_name":"caffeine citrate","eml_section":"Medicines administered to the neonate [c]","formulations":"Parenteral > General injections > IV: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)\nOral > Liquid: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)","indication":"Apnoea of newborn","combined_with":null,"status":"Added","atc_classification":"N06BC01","source":"who.int"},{"medicine_name":"calamine","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Lotion: ","indication":"Pruritus","combined_with":null,"status":"Added","atc_classification":"D02AB","source":"who.int"},{"medicine_name":"calcipotriol","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Cream: 50 \u00b5g per  mL (0.005%)\nLocal > Topical > Lotion: 50 \u00b5g per  mL (0.005%)\nLocal > Topical > Ointment: 50 \u00b5g per  mL (0.005%)","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"D05AX02","source":"who.int"},{"medicine_name":"calcitriol","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":null,"indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"calcium","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 500 mg (elemental calcium)","indication":"Calcium deficiency","combined_with":null,"status":"Added","atc_classification":"A12AA20","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Malignant neoplasm metastasis in large intestine","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Malignant neoplasms of rectum","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium folinate (leucovorin calcium)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 15 mg tablet\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule\nParenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Solid > tablet: 15 mg; 5 mg; 25 mg","indication":"Malignant neoplasms of colon","combined_with":null,"status":"Added","atc_classification":"V03AF03","source":"who.int"},{"medicine_name":"calcium gluconate","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","indication":"Hypermagnesaemia","combined_with":null,"status":"Added","atc_classification":"A12AA03","source":"who.int"},{"medicine_name":"calcium gluconate","eml_section":"Vitamins and minerals","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","indication":"Tetany due to acute calcium deficiency","combined_with":null,"status":"Added","atc_classification":"A12AA03","source":"who.int"},{"medicine_name":"canagliflozin","eml_section":"Oral hypoglycaemic agents","formulations":null,"indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"capecitabine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 150 mg tablet; 500 mg tablet","indication":"Malignant neoplasms of colon","combined_with":null,"status":"Added","atc_classification":"L01BC06","source":"who.int"},{"medicine_name":"capecitabine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 150 mg tablet; 500 mg tablet","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01BC06","source":"who.int"},{"medicine_name":"capecitabine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 150 mg tablet; 500 mg tablet","indication":"Malignant neoplasm metastasis in large intestine","combined_with":null,"status":"Added","atc_classification":"L01BC06","source":"who.int"},{"medicine_name":"capecitabine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 150 mg tablet; 500 mg tablet","indication":"Malignant neoplasms of rectum","combined_with":null,"status":"Added","atc_classification":"L01BC06","source":"who.int"},{"medicine_name":"capreomycin","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 1000 mg powder for injection (vial)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AB30","source":"who.int"},{"medicine_name":"captopril","eml_section":"Medicines used in heart failure","formulations":"Oral > Solid: 25 mg","indication":"Heart failure","combined_with":null,"status":"Removed","atc_classification":"C09AA01","source":"who.int"},{"medicine_name":"carbachol","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":null,"indication":"Acute angle closure with pupillary block","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carbachol","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":null,"indication":"Ocular hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carbachol","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":null,"indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carbamazepine","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 100 mg per 5 mL\nOral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AF01","source":"who.int"},{"medicine_name":"carbamazepine","eml_section":"Medicines for bipolar disorders","formulations":"Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg","indication":"Bipolar or related disorders","combined_with":null,"status":"Added","atc_classification":"N03AF01","source":"who.int"},{"medicine_name":"carbetocin","eml_section":"Uterotonics","formulations":"Parenteral > General injections > IV: 100 \u00b5g per  mL (heat stable)","indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"H01BB03","source":"who.int"},{"medicine_name":"carbimazole","eml_section":"Thyroid hormones and antithyroid medicines","formulations":null,"indication":"Thyrotoxicosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Other specified carcinomas of ovary","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Retinoblastoma","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Malignant neoplasms of nasopharynx","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Malignant neoplasms of lip, oral cavity or pharynx","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Malignant neoplasms of cervix uteri","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carboplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01XA02","source":"who.int"},{"medicine_name":"carvedilol","eml_section":"Antianginal medicines","formulations":null,"indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carvedilol","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carvedilol","eml_section":"Antihypertensive medicines","formulations":null,"indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"carvedilol","eml_section":"Antiarrhythmic medicines","formulations":null,"indication":"Cardiac arrhythmia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"caspofungin","eml_section":"Antifungal medicines","formulations":null,"indication":"Systemic or invasive candidosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"cefalexin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (as monohydrate)\nOral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)","indication":"Chronic obstructive pulmonary disease with acute exacerbation","combined_with":null,"status":"Added","atc_classification":"J01DB01","source":"who.int"},{"medicine_name":"cefalexin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid\nOral > Solid: 250 mg (as monohydrate)\nOral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01DB01","source":"who.int"},{"medicine_name":"cefazolin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","indication":"Other specified prophylactic measures","combined_with":"metronidazole","status":"Added","atc_classification":"J01DB04","source":"who.int"},{"medicine_name":"cefazolin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","indication":"Other specified prophylactic measures","combined_with":null,"status":"Added","atc_classification":"J01DB04","source":"who.int"},{"medicine_name":"cefazolin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","indication":"Bacterial infection of joint","combined_with":null,"status":"Added","atc_classification":"J01DB04","source":"who.int"},{"medicine_name":"cefazolin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","indication":"Osteomyelitis or osteitis","combined_with":null,"status":"Added","atc_classification":"J01DB04","source":"who.int"},{"medicine_name":"cefazolin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","indication":"Surgical site infection","combined_with":null,"status":"Removed","atc_classification":"J01DB04","source":"who.int"},{"medicine_name":"cefepime","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01DE01","source":"who.int"},{"medicine_name":"cefixime","eml_section":"Watch group antibiotics","formulations":"Oral > Liquid: 100 mg per 5 mL powder for oral liquid\nOral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)","indication":"Infectious gastroenteritis or colitis without specification of infectious agent","combined_with":null,"status":"Added","atc_classification":"J01DD08","source":"who.int"},{"medicine_name":"cefixime","eml_section":"Watch group antibiotics","formulations":"Oral > Liquid: 100 mg per 5 mL powder for oral liquid\nOral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)","indication":"Gonococcal infection","combined_with":"azithromycin","status":"Added","atc_classification":"J01DD08","source":"who.int"},{"medicine_name":"cefotaxime","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01DD01","source":"who.int"},{"medicine_name":"ceftaroline","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01DI02","source":"who.int"},{"medicine_name":"ceftazidime","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection","indication":"Endophthalmitis","combined_with":"vancomycin","status":"Added","atc_classification":"J01DD02","source":"who.int"},{"medicine_name":"ceftazidime","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection","indication":"Pseudomonas aeruginosa resistant to other antibiotic","combined_with":null,"status":"Added","atc_classification":"J01DD02","source":"who.int"},{"medicine_name":"ceftazidime + avibactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Added","atc_classification":"J01DD52","source":"who.int"},{"medicine_name":"ceftazidime + avibactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Added","atc_classification":"J01DD52","source":"who.int"},{"medicine_name":"ceftolozane + tazobactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 1 g + 0.5 g powder for injection","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Added","atc_classification":"J01DI54","source":"who.int"},{"medicine_name":"ceftriaxone","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)\nParenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)","indication":"Necrotising fasciitis","combined_with":"metronidazole","status":"Added","atc_classification":"J01DD04","source":"who.int"},{"medicine_name":"ceftriaxone","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)\nParenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01DD04","source":"who.int"},{"medicine_name":"cefuroxime","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection","indication":"Other specified prophylactic measures","combined_with":null,"status":"Added","atc_classification":"J01DC02","source":"who.int"},{"medicine_name":"certolizumab pegol","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Axial spondyloarthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"certolizumab pegol","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"certolizumab pegol","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"certolizumab pegol","eml_section":"Medicines for juvenile joint diseases","formulations":null,"indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"cetirizine","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":null,"indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlorambucil","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 2 mg tablet","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01AA02","source":"who.int"},{"medicine_name":"chlorambucil","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 2 mg tablet","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA02","source":"who.int"},{"medicine_name":"chloramphenicol","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)\nParenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection\nOral > Liquid: 150 mg per 5 mL (as palmitate)\nOral > Solid: 250 mg capsule","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01BA01","source":"who.int"},{"medicine_name":"chlorhexidine","eml_section":"Medicines administered to the neonate [c]","formulations":"Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)\nLocal > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)","indication":"Omphalitis of newborn","combined_with":null,"status":"Added","atc_classification":"D08AC02","source":"who.int"},{"medicine_name":"chlorhexidine","eml_section":"Antiseptics","formulations":"Local > Topical > Solution: 5% (digluconate) for dilution","indication":"Chlorhexidine","combined_with":null,"status":"Added","atc_classification":"D08AC02","source":"who.int"},{"medicine_name":"chlorine base compound","eml_section":"Disinfectants","formulations":"Local > Topical > Powder: 0.1% available chlorine for solution\nLocal > Topical > Liquid: 0.1% available chlorine for solution\nLocal > Topical > Solid: 0.1% available chlorine for solution","indication":"Disinfectant, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Removed","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium ovale","combined_with":null,"status":"Added","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium malariae","combined_with":null,"status":"Added","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)\nOral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Removed","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)\nOral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)\nOral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chloroquine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)","indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"P01BA01","source":"who.int"},{"medicine_name":"chlorothiazide","eml_section":"Antihypertensive medicines","formulations":null,"indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlorothiazide","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chloroxylenol","eml_section":"Disinfectants","formulations":"Local > Topical > Solution: 4.8%","indication":"Phenol disinfectant, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"D08AE05","source":"who.int"},{"medicine_name":"chlortalidone","eml_section":"Antihypertensive medicines","formulations":null,"indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlortalidone","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlortetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlortetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious keratitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlortetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"chlortetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Trachoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"cholera vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against cholera alone","combined_with":null,"status":"Added","atc_classification":"J07AE01","source":"who.int"},{"medicine_name":"ciclesonide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ciclosporin","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 1 mL ampoule concentrate for injection\nOral > Liquid: 100 mg per  mL\nOral > Solid > capsule: 25 mg","indication":"Failure or rejection of transplanted organs or tissues","combined_with":null,"status":"Added","atc_classification":"L04AD01","source":"who.int"},{"medicine_name":"cimetidine","eml_section":"Antiulcer medicines","formulations":"Oral > Solid: 200 mg\nParenteral > General injections > unspecified: 200 mg in 2 mL ampoule","indication":"Peptic ulcer, site unspecified","combined_with":null,"status":"Removed","atc_classification":"A02BA01","source":"who.int"},{"medicine_name":"cimetidine","eml_section":"Antiulcer medicines","formulations":"Oral > Solid: 200 mg\nParenteral > General injections > unspecified: 200 mg in 2 mL ampoule","indication":"Gastro-oesophageal reflux disease","combined_with":null,"status":"Removed","atc_classification":"A02BA01","source":"who.int"},{"medicine_name":"ciprofloxacin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 mg per  mL (as hyclate)\nOral > Liquid: 250 mg per 5 mL (anhydrous)\nOral > Solid: 250 mg (as hydrochloride)\nOral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)","indication":"Inflammatory and other diseases of prostate (mild to moderate)","combined_with":null,"status":"Added","atc_classification":"J01MA02","source":"who.int"},{"medicine_name":"ciprofloxacin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 mg per  mL (as hyclate)\nOral > Liquid: 250 mg per 5 mL (anhydrous)\nOral > Solid: 250 mg (as hydrochloride)\nOral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01MA02","source":"who.int"},{"medicine_name":"ciprofloxacin","eml_section":"Ear, nose and throat medicines [c]","formulations":"Local > Otological > drops: 0.3% (as hydrochloride)","indication":"Infectious diseases of external ear","combined_with":null,"status":"Added","atc_classification":"S02AA15","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Malignant neoplasms of nasopharynx","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Malignant neoplasms of lip, oral cavity or pharynx","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cisplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection\nParenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","indication":"Malignant neoplasms of cervix uteri","combined_with":null,"status":"Added","atc_classification":"L01XA01","source":"who.int"},{"medicine_name":"cladribine","eml_section":"Medicines for multiple sclerosis","formulations":"Oral > Solid > tablet: 10 mg","indication":"Multiple sclerosis","combined_with":null,"status":"Added","atc_classification":"L04AA40","source":"who.int"},{"medicine_name":"cladribine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg per  mL in 10 mL vial; 2 mg per  mL in 5 mL vial","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Removed","atc_classification":"L01BB04","source":"who.int"},{"medicine_name":"clindamycin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)\nOral > Solid: 150 mg (as hydrochloride) capsule\nParenteral > General injections > unspecified: 150 mg per  mL (as phosphate) injection","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01FF01","source":"who.int"},{"medicine_name":"clofazimine","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 100 mg; 50 mg","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04BA01","source":"who.int"},{"medicine_name":"clofazimine","eml_section":"Antileprosy medicines","formulations":"Oral > Solid: 100 mg; 50 mg","indication":"Leprosy","combined_with":null,"status":"Added","atc_classification":"J04BA01","source":"who.int"},{"medicine_name":"clomifene","eml_section":"Ovulation inducers","formulations":"Oral > Solid: 50 mg (citrate)","indication":"Female infertility without specification whether primary or secondary","combined_with":null,"status":"Added","atc_classification":"G03GB02","source":"who.int"},{"medicine_name":"clomipramine","eml_section":"Medicines for obsessive compulsive disorders","formulations":"Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)","indication":"Obsessive-compulsive disorder","combined_with":null,"status":"Added","atc_classification":"N06AA04","source":"who.int"},{"medicine_name":"clonazepam","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 500 \u00b5g","indication":"Generalised myoclonic seizure","combined_with":null,"status":"Removed","atc_classification":"N03AE01","source":"who.int"},{"medicine_name":"clopidogrel","eml_section":"Anti-platelet medicines","formulations":"Oral > Solid: 75 mg; 300 mg","indication":"Acute ischaemic heart disease","combined_with":null,"status":"Added","atc_classification":"B01AC04","source":"who.int"},{"medicine_name":"clopidogrel","eml_section":"Anti-platelet medicines","formulations":"Oral > Solid: 75 mg; 300 mg","indication":"Presence of coronary angioplasty implant or graft","combined_with":null,"status":"Added","atc_classification":"B01AC04","source":"who.int"},{"medicine_name":"clotrimazole","eml_section":"Antifungal medicines","formulations":"Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet","indication":"Vulvovaginal candidosis","combined_with":null,"status":"Added","atc_classification":"G01AF02","source":"who.int"},{"medicine_name":"cloxacillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid\nOral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule\nParenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CF02","source":"who.int"},{"medicine_name":"clozapine","eml_section":"Medicines for psychotic disorders","formulations":"Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg","indication":"Schizophrenia or other primary psychotic disorders","combined_with":null,"status":"Added","atc_classification":"N05AH02","source":"who.int"},{"medicine_name":"coal tar","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 5%","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"D05AA","source":"who.int"},{"medicine_name":"cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR09","source":"who.int"},{"medicine_name":"cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR18","source":"who.int"},{"medicine_name":"cobimetinib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"codeine","eml_section":"Opioid analgesics","formulations":"Oral > Solid: 30 mg tablet (codeine phosphate)","indication":"Pain","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"codeine","eml_section":"Antitussives","formulations":"Oral > Solid: 10 mg tablet (codeine phosphate)","indication":"Cough","combined_with":null,"status":"Removed","atc_classification":"R05DA04","source":"who.int"},{"medicine_name":"codeine","eml_section":"Medicines for diarrhoea","formulations":"Oral > Solid: 30 mg tablet (codeine phosphate)","indication":"Diarrhoea","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"colchicine","eml_section":"Medicines used to treat gout","formulations":"Oral > Solid: 0.5 mg","indication":"Gout","combined_with":null,"status":"Removed","atc_classification":"M04AC01","source":"who.int"},{"medicine_name":"colecalciferol","eml_section":"Vitamins and minerals","formulations":"Oral > Liquid: 400 IU per  mL\nOral > Solid: 400 IU; 1000 IU\n","indication":"Calcium deficiency","combined_with":null,"status":"Added","atc_classification":"A11CC05","source":"who.int"},{"medicine_name":"colecalciferol","eml_section":"Vitamins and minerals","formulations":"Oral > Liquid: 400 IU per  mL\nOral > Solid: 400 IU; 1000 IU\n","indication":"Vitamin D deficiency","combined_with":null,"status":"Added","atc_classification":"A11CC05","source":"who.int"},{"medicine_name":"colecalciferol","eml_section":"Vitamins and minerals","formulations":"Oral > Liquid: 400 IU per  mL\nOral > Solid: 400 IU; 1000 IU\n","indication":"Vitamin D deficiency","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"colecalciferol","eml_section":"Vitamins and minerals","formulations":"Oral > Liquid: 400 IU per  mL\nOral > Solid: 400 IU; 1000 IU\n","indication":"Calcium deficiency","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"colistin (injection)","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01XB01","source":"who.int"},{"medicine_name":"compound sodium lactate solution","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: injectable solution","indication":"Other specified disorders of fluid, electrolyte or acid-base balance","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"compound sodium lactate solution","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: injectable solution","indication":"Hypovolaemic shock","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"condoms","eml_section":"Barrier methods","formulations":"-","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"copper-containing intrauterine device","eml_section":"Intrauterine devices","formulations":"-","indication":"Contact with health services for insertion of contraceptive device","combined_with":null,"status":"Added","atc_classification":"G02BA02","source":"who.int"},{"medicine_name":"crizotinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 200 mg; 250 mg\nOral > Solid > capsule: 200 mg; 250 mg","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Removed","atc_classification":"L01ED01","source":"who.int"},{"medicine_name":"crizotinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 200 mg; 250 mg\nOral > Solid > capsule: 200 mg; 250 mg","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Removed","atc_classification":"L01ED01","source":"who.int"},{"medicine_name":"cyanocobalamin","eml_section":"Antianaemia medicines","formulations":".","indication":"Anaemias or other erythrocyte disorders","combined_with":null,"status":"Removed","atc_classification":"B03BA01","source":"who.int"},{"medicine_name":"cyclizine","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Solid: 50 mg tablet\nParenteral > General injections > unspecified: 50 mg per  mL","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"R06AE03","source":"who.int"},{"medicine_name":"cyclopentolate","eml_section":"Diagnostic agents > Ophthalmic medicines","formulations":null,"indication":"Cycloplegic drug","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"cyclopentolate","eml_section":"Ophthalmological preparations > Mydriatics","formulations":null,"indication":"Anterior uveitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cyclophosphamide","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 25 mg tablet\nParenteral > General injections > unspecified: 500 mg in vial powder for injection\nParenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nOral > Solid: 25 mg; 50 mg\nOral > Solid: 25 mg; 50 mg tablet","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"cycloserine","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 250 mg; 125 mg","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Myeloid leukaemia","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"cytarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection\nParenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"L01BC01","source":"who.int"},{"medicine_name":"dabigatran","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 110 mg; 150 mg","indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"B01AE07","source":"who.int"},{"medicine_name":"dabigatran","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 110 mg; 150 mg","indication":"Other specified atrial fibrillation","combined_with":null,"status":"Added","atc_classification":"B01AE07","source":"who.int"},{"medicine_name":"dabrafenib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 50 mg; 75 mg","indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"L01EC02","source":"who.int"},{"medicine_name":"dacarbazine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01AX04","source":"who.int"},{"medicine_name":"daclatasvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP07","source":"who.int"},{"medicine_name":"daclatasvir + sofosbuvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 60 mg + 400 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP07","source":"who.int"},{"medicine_name":"daclatasvir + sofosbuvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 60 mg + 400 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP08","source":"who.int"},{"medicine_name":"dactinomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 \u00b5g in vial powder for injection","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"L01DA01","source":"who.int"},{"medicine_name":"dactinomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 \u00b5g in vial powder for injection","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01DA01","source":"who.int"},{"medicine_name":"dactinomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 \u00b5g in vial powder for injection","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01DA01","source":"who.int"},{"medicine_name":"dactinomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 \u00b5g in vial powder for injection","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01DA01","source":"who.int"},{"medicine_name":"dactinomycin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 \u00b5g in vial powder for injection","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01DA01","source":"who.int"},{"medicine_name":"dalteparin","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Acute ischaemic heart disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"dalteparin","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"dapagliflozin","eml_section":"Oral hypoglycaemic agents","formulations":null,"indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"dapsone","eml_section":"Antileprosy medicines","formulations":"Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet","indication":"Leprosy","combined_with":null,"status":"Added","atc_classification":"J04BA02","source":"who.int"},{"medicine_name":"daptomycin","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01XX09","source":"who.int"},{"medicine_name":"daratumumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL","indication":"Plasma cell myeloma","combined_with":null,"status":"Removed","atc_classification":"L01FC01","source":"who.int"},{"medicine_name":"darbepoetin alfa","eml_section":"Antianaemia medicines","formulations":null,"indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"darunavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AE10","source":"who.int"},{"medicine_name":"dasabuvir","eml_section":"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 250 mg tablet","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"J05AX16","source":"who.int"},{"medicine_name":"dasatinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet","indication":"Chronic myeloid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01EA02","source":"who.int"},{"medicine_name":"daunorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01DB02","source":"who.int"},{"medicine_name":"daunorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","indication":"Myeloid leukaemia","combined_with":null,"status":"Added","atc_classification":"L01DB02","source":"who.int"},{"medicine_name":"daunorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01DB02","source":"who.int"},{"medicine_name":"deferoxamine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)","indication":"Harmful effects of drugs, medicaments or biological substances, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AC01","source":"who.int"},{"medicine_name":"delafloxacin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 300 mg lyophilized powder for injection\nOral > Solid: 450 mg","indication":"Methicillin resistant Staphylococcus aureus","combined_with":null,"status":"Removed","atc_classification":"J01MA23","source":"who.int"},{"medicine_name":"delamanid","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK06","source":"who.int"},{"medicine_name":"dengue vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BX04","source":"who.int"},{"medicine_name":"desmopressin","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 4 \u00b5g per  mL in 1 mL ampoule (acetate)\nLocal > Nasal > Spray: 10 \u00b5g per  dose (acetate)","indication":"Haemophilia A","combined_with":null,"status":"Added","atc_classification":"H01BA02","source":"who.int"},{"medicine_name":"desmopressin","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 4 \u00b5g per  mL in 1 mL ampoule (acetate)\nLocal > Nasal > Spray: 10 \u00b5g per  dose (acetate)","indication":"Von Willebrand disease","combined_with":null,"status":"Added","atc_classification":"H01BA02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Other medicines administered to the mother","formulations":"Parenteral > General injections > unspecified: 4 mg per  mL (dexamethasone phosphate (as sodium))","indication":"Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)\nOral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)\nOral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)\nOral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)\nOral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)\nOral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":"Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 2 mg per 5 mL\nOral > Solid: 2 mg; 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"C05AA09","source":"who.int"},{"medicine_name":"dexamethasone","eml_section":"Antiemetic medicines","formulations":"Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL\nOral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg\nParenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"H02AB02","source":"who.int"},{"medicine_name":"dextran 40","eml_section":"Plasma substitutes","formulations":".","indication":"Hypovolaemia","combined_with":null,"status":"Removed","atc_classification":"B05AA05","source":"who.int"},{"medicine_name":"dextran 70","eml_section":"Plasma substitutes","formulations":"Parenteral > General injections > IV: 6% injectable solution","indication":"Hypovolaemia","combined_with":null,"status":"Added","atc_classification":"B05AA05","source":"who.int"},{"medicine_name":"diaphragms","eml_section":"Barrier methods","formulations":"-","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"diazepam","eml_section":"Antiseizure medicines","formulations":"\nLocal > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system\nLocal > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"diazepam","eml_section":"Antiseizure medicines","formulations":"\nLocal > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system\nLocal > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N05BA01","source":"who.int"},{"medicine_name":"diazepam","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 2 mg per 5 mL\nOral > Solid: 5 mg; 10 mg\nLocal > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system\nLocal > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube\nParenteral > General injections > unspecified: 5 mg per  mL","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"N05BA01","source":"who.int"},{"medicine_name":"diazoxide","eml_section":"Medicines for hypoglycaemia","formulations":"Oral > Liquid: 50 mg per  mL\nOral > Solid: 50 mg","indication":"Persistent hyperinsulinaemic hypoglycaemia of infancy","combined_with":null,"status":"Added","atc_classification":"V03AH01","source":"who.int"},{"medicine_name":"didanosine","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution\nOral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AF02","source":"who.int"},{"medicine_name":"diethylcarbamazine","eml_section":"Antifilarials","formulations":"Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)","indication":"Lymphatic filariasis","combined_with":null,"status":"Added","atc_classification":"P02CB02","source":"who.int"},{"medicine_name":"digitoxin","eml_section":"Medicines used in heart failure","formulations":"Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule\nOral > Solid: 50 \u00b5g; 100 \u00b5g","indication":"Heart failure","combined_with":null,"status":"Removed","atc_classification":"C01AA04","source":"who.int"},{"medicine_name":"digoxin","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 250 \u00b5g per  mL in 2 mL ampoule\nOral > Liquid: 50 \u00b5g per  mL\nOral > Solid: 62.5 \u00b5g; 250 \u00b5g","indication":"Cardiac arrhythmia","combined_with":null,"status":"Added","atc_classification":"C01AA05","source":"who.int"},{"medicine_name":"digoxin","eml_section":"Medicines used in heart failure","formulations":"Parenteral > General injections > IV: 250 \u00b5g per  mL in 2 mL ampoule; 100 \u00b5g per  mL in 1 mL ampoule\nOral > Liquid: 50 \u00b5g per  mL\nOral > Solid > tablet: 62.5 \u00b5g; 250 \u00b5g; 125 \u00b5g","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C01AA05","source":"who.int"},{"medicine_name":"dihydroartemisinin + piperaquine phosphate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BF05","source":"who.int"},{"medicine_name":"dihydroartemisinin + piperaquine phosphate","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BF05","source":"who.int"},{"medicine_name":"dihydroergocryptine mesylate","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: ","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BC03","source":"who.int"},{"medicine_name":"diloxanide","eml_section":"Antiamoebic and antigiardiasis medicines","formulations":"Oral > Solid: 500 mg (furoate)","indication":"Amoebiasis","combined_with":null,"status":"Added","atc_classification":"P01AC01","source":"who.int"},{"medicine_name":"dimercaprol","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IM: 50 mg per  mL in 2 mL ampoule","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB09","source":"who.int"},{"medicine_name":"diphtheria antitoxin","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial","indication":"Need for immunization against diphtheria alone","combined_with":null,"status":"Added","atc_classification":"J06AA01","source":"who.int"},{"medicine_name":"diphtheria vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against diphtheria alone","combined_with":null,"status":"Added","atc_classification":"J07AF01","source":"who.int"},{"medicine_name":"diphtheria-pertussis-tetanus vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against diphtheria-tetanus-pertussis, combined","combined_with":null,"status":"Removed","atc_classification":"J07AJ52","source":"who.int"},{"medicine_name":"diphtheria-tetanus vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against combinations of infectious diseases","combined_with":null,"status":"Removed","atc_classification":"J07AM51","source":"who.int"},{"medicine_name":"docetaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01CD02","source":"who.int"},{"medicine_name":"docetaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01CD02","source":"who.int"},{"medicine_name":"docetaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"L01CD02","source":"who.int"},{"medicine_name":"docetaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01CD02","source":"who.int"},{"medicine_name":"docusate sodium","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 50 mg per 5 mL oral liquid\nOral > Solid: 100 mg capsule","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A06AA02","source":"who.int"},{"medicine_name":"dolasetron","eml_section":"Medicines for other common symptoms in palliative care","formulations":null,"indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"dolasetron","eml_section":"Antiemetic medicines","formulations":null,"indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"dolutegravir","eml_section":"Antiretrovirals > Integrase inhibitors","formulations":"Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AJ03","source":"who.int"},{"medicine_name":"dolutegravir + lamivudine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR27","source":"who.int"},{"medicine_name":"donepezil","eml_section":"Medicines for diseases of the nervous system","formulations":"Oral > Liquid: 1 mg per  mL (hydrochloride)\nOral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)","indication":"Dementia due to Alzheimer disease","combined_with":null,"status":"Removed","atc_classification":"N06DA02","source":"who.int"},{"medicine_name":"dopamine","eml_section":"Medicines used in heart failure","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C01CA04","source":"who.int"},{"medicine_name":"dopamine","eml_section":"Medicines used in heart failure","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)","indication":"Cardiogenic shock","combined_with":null,"status":"Added","atc_classification":"C01CA04","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Removed","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L01AA01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Kaposi sarcoma of unspecified primary site","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxorubicin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)\nParenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)\nParenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01DB01","source":"who.int"},{"medicine_name":"doxycycline","eml_section":"Access group antibiotics","formulations":"Oral > Solid: 100 mg (as hyclate)\nParenteral > General injections > unspecified: 100 mg in vial powder for injection\nOral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)\nOral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","indication":"Chlamydia trachomatis","combined_with":null,"status":"Added","atc_classification":"J01AA02","source":"who.int"},{"medicine_name":"doxycycline","eml_section":"Access group antibiotics","formulations":"Oral > Solid: 100 mg (as hyclate)\nParenteral > General injections > unspecified: 100 mg in vial powder for injection\nOral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)\nOral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","indication":"Chronic obstructive pulmonary disease with acute exacerbation","combined_with":null,"status":"Added","atc_classification":"J01AA02","source":"who.int"},{"medicine_name":"doxycycline","eml_section":"Access group antibiotics","formulations":"Oral > Solid: 100 mg (as hyclate)\nParenteral > General injections > unspecified: 100 mg in vial powder for injection\nOral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)\nOral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01AA02","source":"who.int"},{"medicine_name":"doxycycline","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"J01AA02","source":"who.int"},{"medicine_name":"doxycycline","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 100 mg (hydrochloride or hyclate)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"J01AA02","source":"who.int"},{"medicine_name":"edoxaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"edoxaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Other specified atrial fibrillation","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"efavirenz","eml_section":"Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors","formulations":"Oral > Solid: 600 mg tablet","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AG03","source":"who.int"},{"medicine_name":"efavirenz + emtricitabine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR06","source":"who.int"},{"medicine_name":"efavirenz + lamivudine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)\n","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR11","source":"who.int"},{"medicine_name":"efavirenz + lamivudine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)\n","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"eflornithine","eml_section":"Medicines for the treatment of 2nd stage African trypanosomiasis","formulations":"Parenteral > General injections > IV: 200 mg per  mL in 50 mL bottle (hydrochloride)","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CX03","source":"who.int"},{"medicine_name":"elbasvir + grazoprevir","eml_section":"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 50 mg + 100 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"J05AP54","source":"who.int"},{"medicine_name":"empagliflozin","eml_section":"Oral hypoglycaemic agents","formulations":"Oral > Solid: 10 mg; 25 mg","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10BK03","source":"who.int"},{"medicine_name":"emtricitabine","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 200 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AF09","source":"who.int"},{"medicine_name":"emtricitabine + rilpivirine + tenofovir alafenamide","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 200 mg + 25 mg + 25 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR19","source":"who.int"},{"medicine_name":"emtricitabine + rilpivirine + tenofovir disoproxil fumarate","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR08","source":"who.int"},{"medicine_name":"emtricitabine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR03","source":"who.int"},{"medicine_name":"emtricitabine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","indication":"Contact with or exposure to human immunodeficiency virus","combined_with":null,"status":"Added","atc_classification":"J05AR03","source":"who.int"},{"medicine_name":"emtricitabine + tenofovir alafenamide","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR17","source":"who.int"},{"medicine_name":"enalapril","eml_section":"Antihypertensive medicines","formulations":"Oral > Liquid: 1 mg per  mL (as hydrogen maleate)\nOral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09AA02","source":"who.int"},{"medicine_name":"enalapril","eml_section":"Medicines used in heart failure","formulations":"Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C09AA02","source":"who.int"},{"medicine_name":"encorafenib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"enoxaparin","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule\nParenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule","indication":"Acute ischaemic heart disease","combined_with":null,"status":"Added","atc_classification":"B01AB05","source":"who.int"},{"medicine_name":"enoxaparin","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule\nParenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule","indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"B01AB05","source":"who.int"},{"medicine_name":"entecavir","eml_section":"Medicines for hepatitis B > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Liquid: 0.05 mg per  mL\nOral > Solid: 0.5 mg; 1 mg","indication":"Chronic hepatitis B","combined_with":null,"status":"Added","atc_classification":"J05AF10","source":"who.int"},{"medicine_name":"enzalutamide","eml_section":"Hormones and antihormones","formulations":"\nOral > Solid: 40 mg","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"enzalutamide","eml_section":"Hormones and antihormones","formulations":"\nOral > Solid: 40 mg","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Removed","atc_classification":"L02BB04","source":"who.int"},{"medicine_name":"ephedrine","eml_section":"Local anaesthetics","formulations":"Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per  mL in 1 mL ampoule (ephedrine hydrochloride)","indication":"Cardiac complications of anaesthesia during labour or delivery","combined_with":null,"status":"Added","atc_classification":"C01CA26","source":"who.int"},{"medicine_name":"epinephrine","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 100 \u00b5g per  mL in 10 mL ampoule (as acid tartrate or hydrochloride)","indication":"Cardiac arrest","combined_with":null,"status":"Added","atc_classification":"C01CA24","source":"who.int"},{"medicine_name":"epinephrine","eml_section":"Ophthalmological preparations > Mydriatics","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)","indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"S01EA01","source":"who.int"},{"medicine_name":"epinephrine","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"C01CA24","source":"who.int"},{"medicine_name":"epinephrine","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)","indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"R03AA01","source":"who.int"},{"medicine_name":"epinephrine","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)","indication":"Anaphylaxis","combined_with":null,"status":"Added","atc_classification":"C01CA24","source":"who.int"},{"medicine_name":"epoetin alfa","eml_section":"Antianaemia medicines","formulations":null,"indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"epoetin beta","eml_section":"Antianaemia medicines","formulations":null,"indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"epoetin theta","eml_section":"Antianaemia medicines","formulations":null,"indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"equine rabies immunoglobulin","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > Locoregional injections > Intradermal: 150 IU per  mL in vial; 200 IU per  mL in vial; 300 IU per  mL in vial; 400 IU per  mL in vial","indication":"Rabies","combined_with":null,"status":"Added","atc_classification":"J06BB05","source":"who.int"},{"medicine_name":"eravacycline","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 50 mg lyophilized powder for injection","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Removed","atc_classification":"J01AA13","source":"who.int"},{"medicine_name":"ergocalciferol","eml_section":"Vitamins and minerals","formulations":"\nOral > Liquid: 250 \u00b5g per  mL (10 000 IU per mL)\nOral > Solid: 1.25 mg (50 000 IU)","indication":"Calcium deficiency","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ergocalciferol","eml_section":"Vitamins and minerals","formulations":"\nOral > Liquid: 250 \u00b5g per  mL (10 000 IU per mL)\nOral > Solid: 1.25 mg (50 000 IU)","indication":"Vitamin D deficiency","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ergocalciferol","eml_section":"Vitamins and minerals","formulations":"\nOral > Liquid: 250 \u00b5g per  mL (10 000 IU per mL)\nOral > Solid: 1.25 mg (50 000 IU)","indication":"Vitamin D deficiency","combined_with":null,"status":"Added","atc_classification":"A11CC01","source":"who.int"},{"medicine_name":"ergocalciferol","eml_section":"Vitamins and minerals","formulations":"\nOral > Liquid: 250 \u00b5g per  mL (10 000 IU per mL)\nOral > Solid: 1.25 mg (50 000 IU)","indication":"Calcium deficiency","combined_with":null,"status":"Added","atc_classification":"A11CC01","source":"who.int"},{"medicine_name":"ergometrine","eml_section":"Uterotonics","formulations":"Parenteral > General injections > unspecified: 200 \u00b5g in 1 mL ampoule (hydrogen maleate)","indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"G02AB03","source":"who.int"},{"medicine_name":"erlotinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 100 mg; 150 mg","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01EB02","source":"who.int"},{"medicine_name":"erythromycin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)\nOral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)\nOral > Solid: 250 mg (as stearate or ethylsuccinate)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01FA01","source":"who.int"},{"medicine_name":"erythromycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 0.5%","indication":"Chlamydial conjunctivitis","combined_with":null,"status":"Added","atc_classification":"S01AA17","source":"who.int"},{"medicine_name":"erythromycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 0.5%","indication":"Gonococcal infection of eye","combined_with":null,"status":"Added","atc_classification":"S01AA17","source":"who.int"},{"medicine_name":"erythropoiesis-stimulating agents","eml_section":"Antianaemia medicines","formulations":"Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"B03XA03","source":"who.int"},{"medicine_name":"erythropoiesis-stimulating agents","eml_section":"Antianaemia medicines","formulations":"Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"B03XA01","source":"who.int"},{"medicine_name":"erythropoiesis-stimulating agents","eml_section":"Antianaemia medicines","formulations":"Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"B03XA02","source":"who.int"},{"medicine_name":"estradiol cypionate + medroxyprogesterone acetate","eml_section":"Injectable hormonal contraceptives","formulations":"Parenteral > General injections > IM: 5 mg + 25 mg","indication":"Contact with health services for reasons associated with reproduction","combined_with":null,"status":"Added","atc_classification":"G03AA08","source":"who.int"},{"medicine_name":"etanercept","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Axial spondyloarthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"etanercept","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"etanercept","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"etanercept","eml_section":"Medicines for juvenile joint diseases","formulations":null,"indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ethambutol","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL\nOral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)","indication":"Other specified tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AK02","source":"who.int"},{"medicine_name":"ethambutol","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL\nOral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK02","source":"who.int"},{"medicine_name":"ethambutol + isoniazid","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 400 mg + 150 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AM03","source":"who.int"},{"medicine_name":"ethambutol + isoniazid + pyrazinamide + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AM06","source":"who.int"},{"medicine_name":"ethambutol + isoniazid + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 275 mg + 75 mg + 150 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK02","source":"who.int"},{"medicine_name":"ethambutol + isoniazid + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 275 mg + 75 mg + 150 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AC01","source":"who.int"},{"medicine_name":"ethambutol + isoniazid + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 275 mg + 75 mg + 150 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB02","source":"who.int"},{"medicine_name":"ethanol","eml_section":"Antiseptics","formulations":"Local > Topical > Solution: 70% (denatured)","indication":"Denatured alcohol","combined_with":null,"status":"Added","atc_classification":"D08AX08","source":"who.int"},{"medicine_name":"ether","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation > solution: ","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Removed","atc_classification":"N01AA01","source":"who.int"},{"medicine_name":"ethinylestradiol + etonogestrel","eml_section":"Intravaginal contraceptives","formulations":"Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"G02BB01","source":"who.int"},{"medicine_name":"ethinylestradiol + levonorgestrel","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 50 \u00b5g + 250 \u00b5g [4]\nOral > Solid: 30 \u00b5g + 150 \u00b5g","indication":"Contact with health services for postcoital contraception","combined_with":null,"status":"Removed","atc_classification":"G03AA07","source":"who.int"},{"medicine_name":"ethinylestradiol + levonorgestrel","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 50 \u00b5g + 250 \u00b5g [4]\nOral > Solid: 30 \u00b5g + 150 \u00b5g","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"G03AA07","source":"who.int"},{"medicine_name":"ethinylestradiol + norethisterone","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 35 \u00b5g + 1 mg","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"G03AA05","source":"who.int"},{"medicine_name":"ethionamide","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AD03","source":"who.int"},{"medicine_name":"ethionamide","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)","indication":"Tuberculous meningitis","combined_with":null,"status":"Added","atc_classification":"J04AD03","source":"who.int"},{"medicine_name":"ethosuximide","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 250 mg per 5 mL\nOral > Solid: 250 mg","indication":"Absence seizures, typical","combined_with":null,"status":"Added","atc_classification":"N03AD01","source":"who.int"},{"medicine_name":"etonogestrel-releasing implant","eml_section":"Implantable contraceptives","formulations":"Implant > Subdermal: 68 mg single rod","indication":"Contact with health services for insertion of contraceptive device","combined_with":null,"status":"Added","atc_classification":"G03AC08","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Myeloid leukaemia","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Retinoblastoma","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"etoposide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule\nOral > Solid: 100 mg capsule\nParenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)\nOral > Solid: 100 mg capsule; 50 mg capsule","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01CB01","source":"who.int"},{"medicine_name":"everolimus","eml_section":"Targeted therapies","formulations":"Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01EG02","source":"who.int"},{"medicine_name":"fentanyl","eml_section":"Opioid analgesics","formulations":"Local > Topical > Transdermal patch: 12 \u00b5g\/hour; 25 \u00b5g\/hour; 50 \u00b5g\/hour; 75 \u00b5g\/hour; 100 \u00b5g\/hour\nOral > Solid: 100 to 800 \u00b5g sub-lingual tablet (as citrate); 200 to 1600 \u00b5g lozenge (as citrate)\nOral > Other: 200 to 1200 \u00b5g buccal film (as citrate)","indication":"Chronic cancer pain","combined_with":null,"status":"Added","atc_classification":"N01AH01","source":"who.int"},{"medicine_name":"fentanyl","eml_section":"Opioid analgesics","formulations":"Local > Topical > Transdermal patch: 12 \u00b5g\/hour; 25 \u00b5g\/hour; 50 \u00b5g\/hour; 75 \u00b5g\/hour; 100 \u00b5g\/hour\nOral > Solid: 100 to 800 \u00b5g sub-lingual tablet (as citrate); 200 to 1600 \u00b5g lozenge (as citrate)\nOral > Other: 200 to 1200 \u00b5g buccal film (as citrate)","indication":"Other specified chronic cancer related pain","combined_with":null,"status":"Removed","atc_classification":"N02AB03","source":"who.int"},{"medicine_name":"ferrous salt","eml_section":"Antianaemia medicines","formulations":"Oral > Liquid: 25 mg per  mL iron (as sulfate)\nOral > Solid: 60 mg iron","indication":"Iron deficiency anaemia","combined_with":null,"status":"Added","atc_classification":"B03AA07","source":"who.int"},{"medicine_name":"ferrous salt","eml_section":"Antianaemia medicines","formulations":"Oral > Liquid: 25 mg per  mL iron (as sulfate)\nOral > Solid: 60 mg iron","indication":"Iron deficiency anaemia","combined_with":null,"status":"Added","atc_classification":"B03AA02","source":"who.int"},{"medicine_name":"ferrous salt + folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 60 mg iron + 2.8 mg","indication":"Iron deficiency anaemia","combined_with":null,"status":"Removed","atc_classification":"B03AD02","source":"who.int"},{"medicine_name":"ferrous salt + folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 60 mg iron + 2.8 mg","indication":"Iron deficiency anaemia","combined_with":null,"status":"Removed","atc_classification":"B03AD03","source":"who.int"},{"medicine_name":"ferrous salt + folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 60 mg iron + 2.8 mg","indication":"Iron deficiency anaemia","combined_with":null,"status":"Removed","atc_classification":"B03AD05","source":"who.int"},{"medicine_name":"fexinidazole","eml_section":"Medicines for the treatment of 1st stage African trypanosomiasis","formulations":"Oral > Solid: 600 mg","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CA03","source":"who.int"},{"medicine_name":"fexinidazole","eml_section":"Medicines for the treatment of 2nd stage African trypanosomiasis","formulations":"Oral > Solid: 600 mg","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CA03","source":"who.int"},{"medicine_name":"fexofenadine","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":null,"indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fifth generation cephalosporins","eml_section":"Reserve group antibiotics","formulations":".","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"filgrastim","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > SC: 120 \u00b5g per 0.2 mL in prefilled syringe; 300 \u00b5g per 0.5 mL in prefilled syringe; 480 \u00b5g per 0.8 mL in prefilled syringe; 300 \u00b5g per  mL in 1 mL vial; 480 \u00b5g per 1.6 mL in 1.6 mL vial","indication":"Acquired neutropaenia","combined_with":null,"status":"Added","atc_classification":"L03AA02","source":"who.int"},{"medicine_name":"fingolimod","eml_section":"Immunomodulators for non-malignant disease","formulations":"Oral > Solid: 0.25 mg; 0.5 mg","indication":"Relapsing-remitting multiple sclerosis","combined_with":null,"status":"Removed","atc_classification":"L04AA27","source":"who.int"},{"medicine_name":"fluconazole","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 2 mg per  mL in vial\nOral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid\nOral > Solid > capsule: 50 mg","indication":"Cryptococcosis","combined_with":null,"status":"Added","atc_classification":"J02AC01","source":"who.int"},{"medicine_name":"fluconazole","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 2 mg per  mL in vial\nOral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid\nOral > Solid > capsule: 50 mg","indication":"Candidosis","combined_with":null,"status":"Added","atc_classification":"J02AC01","source":"who.int"},{"medicine_name":"flucytosine","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 2.5 g per 250 mL infusion\nOral > Solid: 250 mg capsule","indication":"Cryptococcosis","combined_with":null,"status":"Added","atc_classification":"J02AX01","source":"who.int"},{"medicine_name":"fludarabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection\nOral > Solid: 10 mg tablet (fludarabine phosphate)","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01BB05","source":"who.int"},{"medicine_name":"fludrocortisone","eml_section":"Adrenal hormones and synthetic substitutes","formulations":"Oral > Solid: 100 \u00b5g (acetate)","indication":"Adrenocortical insufficiency","combined_with":null,"status":"Added","atc_classification":"H02AA02","source":"who.int"},{"medicine_name":"flunisolide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluorescein","eml_section":"Diagnostic agents > Ophthalmic medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)","indication":"Fluorescein","combined_with":null,"status":"Added","atc_classification":"S01JA01","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Ointment: 5%","indication":"Plantar warts","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Malignant neoplasms of nasopharynx","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Malignant neoplasm metastasis in large intestine","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Malignant neoplasms of rectum","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"fluorouracil","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule\nParenteral > General injections > IV: 50 mg per  mL in vial","indication":"Malignant neoplasms of colon","combined_with":null,"status":"Added","atc_classification":"L01BC02","source":"who.int"},{"medicine_name":"flutamide","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluticasone","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluticasone + formoterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluticasone furoate + vilanterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluvastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Mixed hyperlipidaemia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"fluvastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Coronary atherosclerosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 1 mg tablet; 5 mg tablet\nOral > Solid: 400 \u00b5g","indication":"Folate deficiency anaemia","combined_with":null,"status":"Added","atc_classification":"B03BB01","source":"who.int"},{"medicine_name":"folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 1 mg tablet; 5 mg tablet\nOral > Solid: 400 \u00b5g","indication":"Anencephaly or similar anomalies","combined_with":null,"status":"Added","atc_classification":"B03BB01","source":"who.int"},{"medicine_name":"folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 1 mg tablet; 5 mg tablet\nOral > Solid: 400 \u00b5g","indication":"Spina bifida","combined_with":null,"status":"Added","atc_classification":"B03BB01","source":"who.int"},{"medicine_name":"folic acid","eml_section":"Antianaemia medicines","formulations":"Oral > Solid: 1 mg tablet; 5 mg tablet\nOral > Solid: 400 \u00b5g","indication":"Cephalocele","combined_with":null,"status":"Added","atc_classification":"B03BB01","source":"who.int"},{"medicine_name":"fomepizole","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 5 mg per  mL in 20 mL ampoule (sulfate); 1 g per  mL in 1.5 mL ampoule (base)","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB34","source":"who.int"},{"medicine_name":"fosfomycin (injection)","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01XX01","source":"who.int"},{"medicine_name":"fosfomycin (injection)","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","indication":"Carbapenem resistant Acinetobacter baumannii","combined_with":null,"status":"Added","atc_classification":"J01XX01","source":"who.int"},{"medicine_name":"fosfomycin (injection)","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Added","atc_classification":"J01XX01","source":"who.int"},{"medicine_name":"fosfomycin (injection)","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Added","atc_classification":"J01XX01","source":"who.int"},{"medicine_name":"fourth generation cephalosporins","eml_section":"Watch group antibiotics","formulations":".","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"fresh-frozen plasma","eml_section":"Blood and blood components","formulations":"Parenteral > General injections > IV: ","indication":"Blood transfusion without reported diagnosis","combined_with":null,"status":"Added","atc_classification":"B05AX03","source":"who.int"},{"medicine_name":"fulvestrant","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > IV: 250 mg per 5 mL","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Removed","atc_classification":"L02BA03","source":"who.int"},{"medicine_name":"furosemide","eml_section":"Medicines used in heart failure","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL\nOral > Solid > tablet: 40 mg; 20 mg","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C03CA01","source":"who.int"},{"medicine_name":"furosemide","eml_section":"Diuretics","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL\nOral > Solid > tablet: 40 mg; 20 mg","indication":"Anuria or oliguria","combined_with":null,"status":"Added","atc_classification":"C03CA01","source":"who.int"},{"medicine_name":"furosemide","eml_section":"Diuretics","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule\nOral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL\nOral > Solid > tablet: 40 mg; 20 mg","indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"C03CA01","source":"who.int"},{"medicine_name":"gabapentin","eml_section":"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","formulations":"Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg","indication":"Neuropathic pain","combined_with":null,"status":"Removed","atc_classification":"N02BF01","source":"who.int"},{"medicine_name":"gallamine","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 2 mL ampoule (gallamine triethiodide)","indication":"Muscle relaxants","combined_with":null,"status":"Removed","atc_classification":"M03AC02","source":"who.int"},{"medicine_name":"gatifloxacin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 200 mg; 400 mg","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J01MA16","source":"who.int"},{"medicine_name":"gefitinib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"gemcitabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection","indication":"Other specified carcinomas of ovary","combined_with":null,"status":"Added","atc_classification":"L01BC05","source":"who.int"},{"medicine_name":"gemcitabine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01BC05","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Sepsis without septic shock","combined_with":"amoxicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Sepsis without septic shock","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Sepsis without septic shock","combined_with":"benzylpenicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","combined_with":"benzylpenicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","combined_with":"amoxicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Acute malnutrition in infants, children or adolescents (complicated) [children]","combined_with":"benzylpenicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Acute malnutrition in infants, children or adolescents (complicated) [children]","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Peritonitis (mild-moderate)","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Peritonitis (severe)","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Peritoneal abscess (mild-moderate)","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Peritoneal abscess (severe)","combined_with":"ampicillin","status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Neonatal meningitis","combined_with":null,"status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Gonococcal infection","combined_with":null,"status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Other specified prophylactic measures","combined_with":null,"status":"Added","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01GB03","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)","indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"S02AA14","source":"who.int"},{"medicine_name":"gentamicin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)","indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"S02AA14","source":"who.int"},{"medicine_name":"glass ionomer cement","eml_section":"Dental medicines and preparations","formulations":"Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid","indication":"Dental caries","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"glatiramer acetate","eml_section":"Medicines for multiple sclerosis","formulations":"Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL\nParenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe","indication":"Relapsing-remitting multiple sclerosis","combined_with":null,"status":"Removed","atc_classification":"L03AX13","source":"who.int"},{"medicine_name":"glatiramer acetate","eml_section":"Medicines for multiple sclerosis","formulations":"Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL\nParenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe","indication":"Multiple sclerosis","combined_with":null,"status":"Added","atc_classification":"L03AX13","source":"who.int"},{"medicine_name":"glecaprevir + pibrentasvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP57","source":"who.int"},{"medicine_name":"glibenclamide","eml_section":"Oral hypoglycaemic agents","formulations":"Oral > Solid: 5 mg; 2.5 mg","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10BB01","source":"who.int"},{"medicine_name":"gliclazide","eml_section":"Oral hypoglycaemic agents","formulations":"Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10BB09","source":"who.int"},{"medicine_name":"glucagon","eml_section":"Medicines for hypoglycaemia","formulations":"Parenteral > General injections > unspecified: 1 mg per  mL","indication":"Hypoglycaemia in the context of diabetes","combined_with":null,"status":"Added","atc_classification":"H04AA01","source":"who.int"},{"medicine_name":"glucose","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 5% isotonic; 10% hypertonic\nParenteral > General injections > IV: 50% hypertonic","indication":"Other specified disorders of fluid, electrolyte or acid-base balance","combined_with":null,"status":"Added","atc_classification":"B05CX01","source":"who.int"},{"medicine_name":"glucose","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 5% isotonic; 10% hypertonic\nParenteral > General injections > IV: 50% hypertonic","indication":"Hypoglycaemia without associated diabetes","combined_with":null,"status":"Added","atc_classification":"B05CX01","source":"who.int"},{"medicine_name":"glucose + sodium chloride","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol\/L and Cl- 30 mmol\/L; 5% + 0.9% (equivalent to Na+ 150 mmol\/L and Cl- 150 mmol\/L); 5% + 0.45% (equivalent to Na+ 75 mmol\/L and Cl- 75 mmol\/L)","indication":"Other specified disorders of fluid, electrolyte or acid-base balance","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"glutaral","eml_section":"Disinfectants","formulations":"Local > Topical > Solution: 2%","indication":"Glutaral nonmedicinal","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"glyceryl trinitrate","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 500 \u00b5g sublingual tablet","indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"C01DA02","source":"who.int"},{"medicine_name":"glycopyrronium","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"golimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Axial spondyloarthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"golimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"golimumab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"golimumab","eml_section":"Medicines for juvenile joint diseases","formulations":null,"indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"goserelin","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"goserelin","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"granisetron","eml_section":"Medicines for other common symptoms in palliative care","formulations":null,"indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"granisetron","eml_section":"Antiemetic medicines","formulations":null,"indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"griseofulvin","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 125 mg per 5 mL\nOral > Solid: 125 mg; 250 mg","indication":"Dermatophytosis","combined_with":null,"status":"Added","atc_classification":"D01BA01","source":"who.int"},{"medicine_name":"haemophilus influenzae type b vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AG01","source":"who.int"},{"medicine_name":"haloperidol","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 2 mg per  mL\nOral > Solid: 0.5 mg; 2 mg; 5 mg\nParenteral > General injections > unspecified: 5 mg per  mL in 1-mL ampoule","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"N05AD01","source":"who.int"},{"medicine_name":"halothane","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation > liquid: ","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AB01","source":"who.int"},{"medicine_name":"heparin sodium","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","indication":"Acute ischaemic heart disease","combined_with":null,"status":"Added","atc_classification":"B01AB01","source":"who.int"},{"medicine_name":"heparin sodium","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","indication":"Unstable angina","combined_with":null,"status":"Added","atc_classification":"B01AB01","source":"who.int"},{"medicine_name":"heparin sodium","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"B01AB01","source":"who.int"},{"medicine_name":"hepatitis a vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against viral hepatitis","combined_with":null,"status":"Added","atc_classification":"J07BC02","source":"who.int"},{"medicine_name":"hepatitis b vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against viral hepatitis","combined_with":null,"status":"Added","atc_classification":"J07BC01","source":"who.int"},{"medicine_name":"homatropine","eml_section":"Ophthalmological preparations > Mydriatics","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)\n","indication":"Anterior uveitis","combined_with":null,"status":"Removed","atc_classification":"S01FA05","source":"who.int"},{"medicine_name":"homatropine","eml_section":"Ophthalmological preparations > Mydriatics","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)\n","indication":"Anterior uveitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"human papilloma virus (hpv) vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BM01","source":"who.int"},{"medicine_name":"hydralazine","eml_section":"Antihypertensive medicines","formulations":"Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)\nOral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)\nOral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)","indication":"Essential hypertension","combined_with":null,"status":"Removed","atc_classification":"C02DB02","source":"who.int"},{"medicine_name":"hydralazine","eml_section":"Antihypertensive medicines","formulations":"Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)\nOral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)\nOral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)","indication":"Gestational hypertension","combined_with":null,"status":"Added","atc_classification":"C02DB02","source":"who.int"},{"medicine_name":"hydrochlorothiazide","eml_section":"Antihypertensive medicines","formulations":"Oral > Liquid: 50 mg per 5 mL\nOral > Solid: 25 mg; 12.5 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C03AA03","source":"who.int"},{"medicine_name":"hydrochlorothiazide","eml_section":"Medicines used in heart failure","formulations":"Oral > Liquid: 50 mg per 5 mL\nOral > Solid: 25 mg","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C03AA03","source":"who.int"},{"medicine_name":"hydrochlorothiazide","eml_section":"Diuretics","formulations":"Oral > Solid: 25 mg","indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"C03AA03","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"H02AB09","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"H02AB09","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"H02AB09","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Adrenal hormones and synthetic substitutes","formulations":"Oral > Solid: 5 mg; 10 mg; 20 mg","indication":"Adrenocortical insufficiency","combined_with":null,"status":"Added","atc_classification":"H02AB09","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Ophthalmological preparations > Anti-inflammatory agents","formulations":"Local > Ophthalmological > Ointment: 1% (acetate)","indication":"Scleritis","combined_with":null,"status":"Removed","atc_classification":"S01BA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Ophthalmological preparations > Anti-inflammatory agents","formulations":"Local > Ophthalmological > Ointment: 1% (acetate)","indication":"Anterior uveitis","combined_with":null,"status":"Removed","atc_classification":"S01BA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":"Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)","indication":"Anaphylaxis","combined_with":null,"status":"Added","atc_classification":"H02AB09","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Anti-inflammatory medicines","formulations":"Local > Rectal > Suppository: 25 mg (acetate)\nLocal > Rectal > Retention enema: 100 mg per 60 mL","indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"A07EA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Anti-inflammatory medicines","formulations":"Local > Rectal > Suppository: 25 mg (acetate)\nLocal > Rectal > Retention enema: 100 mg per 60 mL","indication":"Ulcerative colitis","combined_with":null,"status":"Added","atc_classification":"A07EA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 1% (acetate)\nLocal > Topical > Ointment: 1% (acetate)","indication":"Dermatitis or eczema","combined_with":null,"status":"Added","atc_classification":"D07AA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 1% (acetate)\nLocal > Topical > Ointment: 1% (acetate)","indication":"Lichen planus","combined_with":null,"status":"Added","atc_classification":"D07AA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 1% (acetate)\nLocal > Topical > Ointment: 1% (acetate)","indication":"Pruritus due to skin disorder","combined_with":null,"status":"Added","atc_classification":"D07AA02","source":"who.int"},{"medicine_name":"hydrocortisone","eml_section":"Dermatological medicines > Anti-inflammatory and antipruritic medicines","formulations":"Local > Topical > Cream: 1% (acetate)\nLocal > Topical > Ointment: 1% (acetate)","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"D07AA02","source":"who.int"},{"medicine_name":"hydromorphone","eml_section":"Opioid analgesics","formulations":null,"indication":"Pain","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"hydroxocobalamin","eml_section":"Antianaemia medicines","formulations":"Parenteral > General injections > IM: 1 mg per  mL in 1 mL ampoule (as acetate); 1 mg per  mL in 1 mL ampoule (as hydrochloride); 1 mg per  mL in 1 mL ampoule (as sulfate)","indication":"Megaloblastic anaemia due to vitamin B12 deficiency","combined_with":null,"status":"Added","atc_classification":"B03BA03","source":"who.int"},{"medicine_name":"hydroxycarbamide (hydroxyurea)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g\nOral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg","indication":"Squamous cell carcinoma of oropharynx","combined_with":null,"status":"Removed","atc_classification":"L01XX05","source":"who.int"},{"medicine_name":"hydroxycarbamide (hydroxyurea)","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g\nOral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg","indication":"Chronic myeloid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01XX05","source":"who.int"},{"medicine_name":"hydroxycarbamide (hydroxyurea)","eml_section":"Other medicines for haemoglobinopathies","formulations":"Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg","indication":"Other specified sickle cell disorders or other haemoglobinopathies","combined_with":null,"status":"Added","atc_classification":"L01XX05","source":"who.int"},{"medicine_name":"hydroxychloroquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":null,"indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"hydroxychloroquine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 200 mg (as sulfate)","indication":"Systemic lupus erythematosus","combined_with":null,"status":"Added","atc_classification":"P01BA02","source":"who.int"},{"medicine_name":"hydroxychloroquine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 200 mg (as sulfate)","indication":"Cutaneous lupus erythematosus of unspecified type","combined_with":null,"status":"Added","atc_classification":"P01BA02","source":"who.int"},{"medicine_name":"hyoscine butylbromide","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Parenteral > General injections > unspecified: 20 mg per  mL injection","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A03BB01","source":"who.int"},{"medicine_name":"hyoscine hydrobromide","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch\nParenteral > General injections > unspecified: 400 \u00b5g per  mL injection; 600 \u00b5g per  mL injection","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A04AD01","source":"who.int"},{"medicine_name":"hypochlorous acid","eml_section":"Antiseptics","formulations":"Local > Topical > Solution: ","indication":"Disinfectant, not elsewhere classified","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"ibrutinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 140 mg","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01EL01","source":"who.int"},{"medicine_name":"ibuprofen","eml_section":"Medicines administered to the neonate [c]","formulations":"Parenteral > General injections > IV: 5 mg per  mL","indication":"Patent arterial duct","combined_with":null,"status":"Added","atc_classification":"C01EB16","source":"who.int"},{"medicine_name":"ibuprofen","eml_section":"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","formulations":"Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL\nOral > Solid > tablet: 200 mg; 400 mg; 600 mg","indication":"Pain","combined_with":null,"status":"Added","atc_classification":"M01AE01","source":"who.int"},{"medicine_name":"ibuprofen","eml_section":"Antimigraine medicines > For treatment of acute attack","formulations":"Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL\nOral > Solid > tablet: 200 mg; 400 mg","indication":"Migraine","combined_with":null,"status":"Added","atc_classification":"M01AE01","source":"who.int"},{"medicine_name":"idoxuridine","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.1%\nLocal > Ophthalmological > Ointment: 0.2%","indication":"Herpes simplex keratitis","combined_with":null,"status":"Removed","atc_classification":"S01AD01","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"ifosfamide","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection\nParenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01AA06","source":"who.int"},{"medicine_name":"imatinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 100 mg; 400 mg","indication":"B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1","combined_with":null,"status":"Added","atc_classification":"L01EA01","source":"who.int"},{"medicine_name":"imatinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 100 mg; 400 mg","indication":"Gastrointestinal stromal tumour of unspecified gastrointestinal sites","combined_with":null,"status":"Added","atc_classification":"L01EA01","source":"who.int"},{"medicine_name":"imatinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 100 mg; 400 mg","indication":"Chronic myeloid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01EA01","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection\n","indication":"Peritonitis (severe)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection\n","indication":"Peritoneal abscess (severe)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection\n","indication":"Neutropenia (high-risk)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection\n","indication":"Pseudomonas aeruginosa resistant to other antibiotic","combined_with":null,"status":"Removed","atc_classification":"J01DH51","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection\n","indication":"Antibiotic resistant Acinetobacter baumannii","combined_with":null,"status":"Removed","atc_classification":"J01DH51","source":"who.int"},{"medicine_name":"imipenem + cilastatin","eml_section":"Antituberculosis medicines","formulations":null,"indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"imipenem + cilastatin + relebactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","indication":"Other specified other antibiotic resistant Enterobacterales","combined_with":null,"status":"Removed","atc_classification":"J01DH56","source":"who.int"},{"medicine_name":"imipenem + cilastatin + relebactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Removed","atc_classification":"J01DH56","source":"who.int"},{"medicine_name":"imipenem + cilastatin + relebactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Removed","atc_classification":"J01DH56","source":"who.int"},{"medicine_name":"indapamide","eml_section":"Antihypertensive medicines","formulations":null,"indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"indapamide","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"indinavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 400 mg (as sulfate)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AE02","source":"who.int"},{"medicine_name":"indometacin","eml_section":"Medicines administered to the neonate [c]","formulations":null,"indication":"Patent arterial duct","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"infliximab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Axial spondyloarthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"infliximab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"infliximab","eml_section":"Immunomodulators for non-malignant disease","formulations":null,"indication":"Rheumatoid arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"infliximab","eml_section":"Medicines for juvenile joint diseases","formulations":null,"indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"influenza vaccine (seasonal)","eml_section":"Recommendations for immunization programmes with certain characteristics","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against influenza","combined_with":null,"status":"Added","atc_classification":"J07BB01","source":"who.int"},{"medicine_name":"influenza vaccine (seasonal)","eml_section":"Recommendations for immunization programmes with certain characteristics","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against influenza","combined_with":null,"status":"Added","atc_classification":"J07BB02","source":"who.int"},{"medicine_name":"influenza vaccine (seasonal)","eml_section":"Recommendations for immunization programmes with certain characteristics","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against influenza","combined_with":null,"status":"Added","atc_classification":"J07BB03","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AD05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AC04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AD04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB06","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE06","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AD05","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AC04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AD04","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AB06","source":"who.int"},{"medicine_name":"insulin analogues","eml_section":"Insulins","formulations":"Not specified","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE06","source":"who.int"},{"medicine_name":"insulin degludec","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin degludec","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin degludec","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin detemir","eml_section":"Insulins","formulations":null,"indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin detemir","eml_section":"Insulins","formulations":null,"indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin detemir","eml_section":"Insulins","formulations":null,"indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin glargine","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10AE04","source":"who.int"},{"medicine_name":"insulin glargine","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"insulin glargine","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 units per  mL\n","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"intraperitoneal dialysis solution","eml_section":"Peritoneal dialysis solution","formulations":"parenteral solution","indication":"Care involving peritoneal dialysis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"iodine","eml_section":"Vitamins and minerals","formulations":"Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule\nOral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle\nOral > Solid: 190 mg","indication":"Iodine deficiency","combined_with":null,"status":"Added","atc_classification":"H03CA","source":"who.int"},{"medicine_name":"iodine","eml_section":"Antiseptics","formulations":null,"indication":"Povidone iodine","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"iohexol","eml_section":"Diagnostic agents > Radiocontrast media","formulations":"Parenteral > General injections > unspecified: 140 to 350 mg iodine per  mL in 5 mL ampoule; 140 to 350 mg iodine per  mL in 10 mL ampoule; 140 to 350 mg iodine per  mL in 20 mL ampoule","indication":"X-ray contrast media, iodinated","combined_with":null,"status":"Added","atc_classification":"V08AB02","source":"who.int"},{"medicine_name":"ipecacuanha","eml_section":"Antidotes and other substances used in poisonings > Non-specific","formulations":"Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine","indication":"Unspecified injury, poisoning or certain other consequences of external causes","combined_with":null,"status":"Removed","atc_classification":"V03AB01","source":"who.int"},{"medicine_name":"ipratropium bromide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Respiratory > Inhalation > aerosol: 20 \u00b5g per  dose","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"R03BB01","source":"who.int"},{"medicine_name":"ipratropium bromide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Respiratory > Inhalation > aerosol: 20 \u00b5g per  dose","indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"R03BB01","source":"who.int"},{"medicine_name":"irinotecan","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","indication":"Malignant neoplasm metastasis in large intestine","combined_with":null,"status":"Added","atc_classification":"L01CE02","source":"who.int"},{"medicine_name":"irinotecan","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01CE02","source":"who.int"},{"medicine_name":"irinotecan","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01CE02","source":"who.int"},{"medicine_name":"isoflurane","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation > liquid: ","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AB06","source":"who.int"},{"medicine_name":"isoniazid","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL\nOral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet","indication":"Other specified tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AC01","source":"who.int"},{"medicine_name":"isoniazid","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL\nOral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AC01","source":"who.int"},{"medicine_name":"isoniazid + pyrazinamide + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AM05","source":"who.int"},{"medicine_name":"isoniazid + pyridoxine + sulfamethoxazole + trimethoprim","eml_section":"Medicines for prevention of HIV-related opportunistic infections","formulations":"Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)","indication":"Other specified prophylactic measures","combined_with":null,"status":"Added","atc_classification":"J04AC51","source":"who.int"},{"medicine_name":"isoniazid + rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AM02","source":"who.int"},{"medicine_name":"isoniazid + rifapentine","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 300 mg + 300 mg tablet (scored)","indication":"Latent tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AC51","source":"who.int"},{"medicine_name":"isoprenaline","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 20 \u00b5g per  mL in ampoule (hydrochloride)\nOral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)","indication":"Bradycardia","combined_with":null,"status":"Removed","atc_classification":"C01CA02","source":"who.int"},{"medicine_name":"isoprenaline","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 20 \u00b5g per  mL in ampoule (hydrochloride)\nOral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)","indication":"Cardiogenic shock","combined_with":null,"status":"Removed","atc_classification":"C01CA02","source":"who.int"},{"medicine_name":"isosorbide dinitrate","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 5 mg sublingual tablet","indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"C01DA08","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Chronic pulmonary aspergillosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Chromoblastomycosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Histoplasmosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Talaromycosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Sporotrichosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"itraconazole","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 10 mg per  mL\nOral > Solid: 100 mg","indication":"Paracoccidioidomycosis","combined_with":null,"status":"Added","atc_classification":"J02AC02","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 3 mg","indication":"Strongyloidiasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 3 mg","indication":"Ascariasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 3 mg","indication":"Trichuriasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 3 mg","indication":"Hookworm diseases","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 3 mg","indication":"Ancylostomiasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Antifilarials","formulations":"Oral > Solid > tablet: 3 mg","indication":"Onchocerciasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Antifilarials","formulations":"Oral > Solid > tablet: 3 mg","indication":"Lymphatic filariasis","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"ivermectin","eml_section":"Medicines for ectoparasitic infections","formulations":"Oral > Solid > tablet: 3 mg","indication":"Scabies","combined_with":null,"status":"Added","atc_classification":"P02CF01","source":"who.int"},{"medicine_name":"kanamycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"kanamycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"kanamycin (injection)","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 1000 mg powder for injection (vial)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J01GB04","source":"who.int"},{"medicine_name":"ketamine","eml_section":"General anaesthetics and oxygen > Injectable medicines","formulations":"Parenteral > General injections > unspecified: 50 mg per  mL in 10 mL vial (as hydrochloride)","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AX03","source":"who.int"},{"medicine_name":"lactulose","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A06AD11","source":"who.int"},{"medicine_name":"lamivudine","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Liquid: 50 mg per 5 mL\nOral > Solid: 150 mg tablet","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AF05","source":"who.int"},{"medicine_name":"lamivudine + nevirapine + zidovudine","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AR05","source":"who.int"},{"medicine_name":"lamivudine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":null,"indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"lamivudine + tenofovir","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":null,"indication":"Contact with or exposure to human immunodeficiency virus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"lamivudine + zidovudine","eml_section":"Fixed-dose combinations of antiretrovirals","formulations":"Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR01","source":"who.int"},{"medicine_name":"lamotrigine","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AX09","source":"who.int"},{"medicine_name":"latanoprost","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 50 \u00b5g per  mL eye drops","indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"S01EE01","source":"who.int"},{"medicine_name":"ledipasvir + sofosbuvir","eml_section":"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 90 mg + 400 mg tablet","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP51","source":"who.int"},{"medicine_name":"lenalidomide","eml_section":"Immunomodulators","formulations":"Oral > Solid: 25 mg","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L04AX04","source":"who.int"},{"medicine_name":"leuprorelin","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L02AE02","source":"who.int"},{"medicine_name":"leuprorelin","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"L02AE02","source":"who.int"},{"medicine_name":"levamisole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 50 mg  (as hydrochloride); 150 mg  (as hydrochloride)","indication":"Ascariasis","combined_with":null,"status":"Added","atc_classification":"P02CE01","source":"who.int"},{"medicine_name":"levetiracetam","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 100 mg per  mL\nOral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg\nParenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AX14","source":"who.int"},{"medicine_name":"levetiracetam","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 100 mg per  mL\nOral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg\nParenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N03AX14","source":"who.int"},{"medicine_name":"levodopa","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 250 mg","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BA01","source":"who.int"},{"medicine_name":"levodopa + benserazide","eml_section":"Medicines for parkinsonism","formulations":null,"indication":"Parkinson disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"levodopa + carbidopa","eml_section":"Medicines for parkinsonism","formulations":"Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet","indication":"Parkinson disease","combined_with":null,"status":"Added","atc_classification":"N04BA02","source":"who.int"},{"medicine_name":"levofloxacin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01MA12","source":"who.int"},{"medicine_name":"levonorgestrel","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 750 \u00b5g [2]; 1.5 mg [1]\nOral > Solid: 30 \u00b5g","indication":"Contact with health services for postcoital contraception","combined_with":null,"status":"Added","atc_classification":"G03AD01","source":"who.int"},{"medicine_name":"levonorgestrel","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 750 \u00b5g [2]; 1.5 mg [1]\nOral > Solid: 30 \u00b5g","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"G03AC03","source":"who.int"},{"medicine_name":"levonorgestrel","eml_section":"Intrauterine devices","formulations":"Intrauterine system with reservoir containing 52 mg of levonorgestrel.","indication":"Contact with health services for insertion of contraceptive device","combined_with":null,"status":"Added","atc_classification":"G02BA03","source":"who.int"},{"medicine_name":"levonorgestrel-releasing implant","eml_section":"Implantable contraceptives","formulations":"Implant > Subdermal: 75 mg per  rod (two-rods)","indication":"Contact with health services for insertion of contraceptive device","combined_with":null,"status":"Added","atc_classification":"G03AC03","source":"who.int"},{"medicine_name":"levothyroxine","eml_section":"Thyroid hormones and antithyroid medicines","formulations":"Oral > Solid: 50 \u00b5g (sodium salt); 100 \u00b5g (sodium salt); 25 \u00b5g (sodium salt)","indication":"Hypothyroidism","combined_with":null,"status":"Added","atc_classification":"H03AA01","source":"who.int"},{"medicine_name":"lidocaine","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule (hydrochloride)","indication":"Ventricular tachyarrhythmia","combined_with":null,"status":"Added","atc_classification":"C01BB01","source":"who.int"},{"medicine_name":"lidocaine","eml_section":"Local anaesthetics","formulations":"Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution\nParenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)\nLocal > Topical > unspecified: 2 to 4% (hydrochloride)","indication":"Local anaesthetics","combined_with":null,"status":"Added","atc_classification":"N01BB02","source":"who.int"},{"medicine_name":"lidocaine + epinephrine","eml_section":"Local anaesthetics","formulations":"Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial\nLocal > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine","indication":"Local anaesthetics","combined_with":null,"status":"Added","atc_classification":"N01BB52","source":"who.int"},{"medicine_name":"lindane","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Cream: 1%\nLocal > Topical > Lotion: 1%","indication":"Scabies","combined_with":null,"status":"Removed","atc_classification":"P03AB02","source":"who.int"},{"medicine_name":"linezolid","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 2 mg per  mL in 300 mL bag\nOral > Liquid: 100 mg per 5 mL powder for oral liquid\nOral > Solid: 400 mg tablet; 600 mg tablet","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01XX08","source":"who.int"},{"medicine_name":"linezolid","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01XX08","source":"who.int"},{"medicine_name":"lisinopril + amlodipine","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09BB03","source":"who.int"},{"medicine_name":"lisinopril + hydrochlorothiazide","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09BA03","source":"who.int"},{"medicine_name":"lisocabtagene maraleucel","eml_section":"Antineoplastics and supportive medicines","formulations":null,"indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"lithium carbonate","eml_section":"Medicines for bipolar disorders","formulations":"Oral > Solid: 300 mg","indication":"Bipolar or related disorders","combined_with":null,"status":"Added","atc_classification":"N05AN01","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE06","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE05","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 1 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE04","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE06","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE05","source":"who.int"},{"medicine_name":"long-acting insulin analogues","eml_section":"Insulins","formulations":"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10AE04","source":"who.int"},{"medicine_name":"loperamide","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Solid: 2 mg solid oral dosage form","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A07DA03","source":"who.int"},{"medicine_name":"lopinavir + ritonavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AR10","source":"who.int"},{"medicine_name":"loratadine","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":"Oral > Liquid: 1 mg per  mL\nOral > Solid: 10 mg","indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"R06AX13","source":"who.int"},{"medicine_name":"lorazepam","eml_section":"Antiseizure medicines","formulations":"Parenteral > General injections > IV: 2 mg per  mL in 1 mL ampoule; 4 mg per  mL in 1 mL ampoule","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N05BA06","source":"who.int"},{"medicine_name":"losartan","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09CA01","source":"who.int"},{"medicine_name":"losartan","eml_section":"Medicines used in heart failure","formulations":"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C09CA01","source":"who.int"},{"medicine_name":"lovastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Mixed hyperlipidaemia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"lovastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Coronary atherosclerosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"lugol's solution","eml_section":"Thyroid hormones and antithyroid medicines","formulations":"Oral > Liquid: 13% w\/v (about 130 mg\/mL total iodine)","indication":"Thyrotoxicosis","combined_with":null,"status":"Added","atc_classification":"H03CA","source":"who.int"},{"medicine_name":"magnesium sulfate","eml_section":"Antiseizure medicines","formulations":"Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight\/volume)\nParenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight\/volume)","indication":"Severe pre-eclampsia","combined_with":null,"status":"Added","atc_classification":"B05XA05","source":"who.int"},{"medicine_name":"magnesium sulfate","eml_section":"Antiseizure medicines","formulations":"Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight\/volume)\nParenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight\/volume)","indication":"Eclampsia","combined_with":null,"status":"Added","atc_classification":"B05XA05","source":"who.int"},{"medicine_name":"mannitol","eml_section":"Diuretics","formulations":"Parenteral > General injections > IV: 10% solution; 20% solution","indication":"Ocular hypertension","combined_with":null,"status":"Added","atc_classification":"B05BC01","source":"who.int"},{"medicine_name":"mannitol","eml_section":"Diuretics","formulations":"Parenteral > General injections > IV: 10% solution; 20% solution","indication":"Cerebral oedema","combined_with":null,"status":"Added","atc_classification":"B05BC01","source":"who.int"},{"medicine_name":"measles vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against measles alone","combined_with":null,"status":"Added","atc_classification":"J07BD01","source":"who.int"},{"medicine_name":"mebendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","indication":"Ascariasis","combined_with":null,"status":"Added","atc_classification":"P02CA01","source":"who.int"},{"medicine_name":"mebendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","indication":"Enterobiasis","combined_with":null,"status":"Added","atc_classification":"P02CA01","source":"who.int"},{"medicine_name":"mebendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","indication":"Trichuriasis","combined_with":null,"status":"Added","atc_classification":"P02CA01","source":"who.int"},{"medicine_name":"mebendazole","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","indication":"Hookworm diseases","combined_with":null,"status":"Added","atc_classification":"P02CA01","source":"who.int"},{"medicine_name":"mebendazole","eml_section":"Cysticidal medicines","formulations":"Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)","indication":"Other specified echinococcosis","combined_with":null,"status":"Added","atc_classification":"P02CA01","source":"who.int"},{"medicine_name":"medroxyprogesterone acetate","eml_section":"Injectable hormonal contraceptives","formulations":"Parenteral > General injections > IM: 150 mg per  mL in 1 mL vial\nParenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system","indication":"Contact with health services for reasons associated with reproduction","combined_with":null,"status":"Added","atc_classification":"G03AC06","source":"who.int"},{"medicine_name":"medroxyprogesterone acetate","eml_section":"Progestogens","formulations":"Oral > Solid: 5 mg","indication":"Excessive menstruation with irregular cycle","combined_with":null,"status":"Added","atc_classification":"G03DA02","source":"who.int"},{"medicine_name":"mefloquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 250 mg tablet (hydrochloride)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BC02","source":"who.int"},{"medicine_name":"mefloquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 250 mg tablet (hydrochloride)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BC02","source":"who.int"},{"medicine_name":"mefloquine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 250 mg tablet (hydrochloride)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BC02","source":"who.int"},{"medicine_name":"meglumine antimoniate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","indication":"Visceral leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB01","source":"who.int"},{"medicine_name":"meglumine antimoniate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","indication":"Mucocutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB01","source":"who.int"},{"medicine_name":"meglumine antimoniate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","indication":"Cutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB01","source":"who.int"},{"medicine_name":"meglumine iotroxate","eml_section":"Diagnostic agents > Radiocontrast media","formulations":"Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL","indication":"X-ray contrast media, iodinated","combined_with":null,"status":"Added","atc_classification":"V08AC02","source":"who.int"},{"medicine_name":"melarsoprol","eml_section":"Medicines for the treatment of 2nd stage African trypanosomiasis","formulations":"Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CD01","source":"who.int"},{"medicine_name":"melphalan","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection\nOral > Solid: 2 mg","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L01AA03","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH01","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH02","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH03","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH04","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH05","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH06","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH07","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH08","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH09","source":"who.int"},{"medicine_name":"meningococcal meningitis vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AH10","source":"who.int"},{"medicine_name":"mercaptopurine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg tablet\nOral > Liquid: 20 mg per  mL","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01BB02","source":"who.int"},{"medicine_name":"mercaptopurine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg tablet\nOral > Liquid: 20 mg per  mL","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01BB02","source":"who.int"},{"medicine_name":"mercaptopurine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg tablet\nOral > Liquid: 20 mg per  mL","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01BB02","source":"who.int"},{"medicine_name":"mercaptopurine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg tablet\nOral > Liquid: 20 mg per  mL","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"L01BB02","source":"who.int"},{"medicine_name":"meropenem","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","indication":"Neonatal meningitis","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"meropenem","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","indication":"Peritonitis (severe)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"meropenem","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","indication":"Peritoneal abscess (severe)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"meropenem","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","indication":"Neutropenia (high-risk)","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"meropenem","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01DH02","source":"who.int"},{"medicine_name":"meropenem + vaborbactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Added","atc_classification":"J01DH52","source":"who.int"},{"medicine_name":"meropenem + vaborbactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Added","atc_classification":"J01DH52","source":"who.int"},{"medicine_name":"meropenem + vaborbactam","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","indication":"Carbapenem resistant Acinetobacter baumannii","combined_with":null,"status":"Added","atc_classification":"J01DH52","source":"who.int"},{"medicine_name":"mesalazine","eml_section":"Anti-inflammatory medicines","formulations":null,"indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"mesalazine","eml_section":"Anti-inflammatory medicines","formulations":null,"indication":"Ulcerative colitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Osteosarcoma of bone and articular cartilage of other specified sites","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"mesna","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule\nOral > Solid: 400 mg; 600 mg","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"V03AF01","source":"who.int"},{"medicine_name":"metformin","eml_section":"Oral hypoglycaemic agents","formulations":"Oral > Solid: 500 mg (hydrochloride)","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Added","atc_classification":"A10BA02","source":"who.int"},{"medicine_name":"methadone","eml_section":"Medicines for opioid use disorders","formulations":"Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)","indication":"Opioid dependence","combined_with":null,"status":"Added","atc_classification":"N07BC02","source":"who.int"},{"medicine_name":"methadone","eml_section":"Opioid analgesics","formulations":"Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)\nOral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)","indication":"Chronic cancer pain","combined_with":null,"status":"Added","atc_classification":"N07BC02","source":"who.int"},{"medicine_name":"methimazole","eml_section":"Thyroid hormones and antithyroid medicines","formulations":"Oral > Solid: 5 mg; 10 mg; 20 mg","indication":"Thyrotoxicosis","combined_with":null,"status":"Added","atc_classification":"H03BB02","source":"who.int"},{"medicine_name":"methionine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Oral > Solid: 250 mg (DL)","indication":"Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs","combined_with":null,"status":"Removed","atc_classification":"V03AB26","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Osteosarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)\nOral > Solid: 2.5 mg (as sodium salt)\nParenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"L01BA01","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"L04AX03","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid > tablet: 2.5 mg (as sodium salt)","indication":"Rheumatoid arthritis, serology unspecified","combined_with":null,"status":"Added","atc_classification":"L04AX03","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > SC: pre-filled syringe in multiple strengths","indication":"Crohn disease site","combined_with":null,"status":"Removed","atc_classification":"L04AX03","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > SC: pre-filled syringe in multiple strengths","indication":"Psoriatic arthritis","combined_with":null,"status":"Removed","atc_classification":"L04AX03","source":"who.int"},{"medicine_name":"methotrexate","eml_section":"Medicines for juvenile joint diseases","formulations":"Oral > Solid > tablet: 2.5 mg (as sodium salt)","indication":"Juvenile idiopathic arthritis","combined_with":null,"status":"Added","atc_classification":"L04AX03","source":"who.int"},{"medicine_name":"methoxy polyethylene glycol-epoetin beta","eml_section":"Antianaemia medicines","formulations":null,"indication":"Anaemia due to chronic disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"methyldopa","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 250 mg","indication":"Essential hypertension","combined_with":null,"status":"Removed","atc_classification":"C02AB01","source":"who.int"},{"medicine_name":"methyldopa","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 250 mg","indication":"Gestational hypertension","combined_with":null,"status":"Added","atc_classification":"C02AB01","source":"who.int"},{"medicine_name":"methylergometrine","eml_section":"Uterotonics","formulations":null,"indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"methylphenidate","eml_section":"Medicines for mental and behavioural disorders","formulations":"Multiple formulations and strengths.","indication":"Attention deficit hyperactivity disorder","combined_with":null,"status":"Removed","atc_classification":"N06BA04","source":"who.int"},{"medicine_name":"methylprednisolone","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"H02AB04","source":"who.int"},{"medicine_name":"methylprednisolone","eml_section":"Hormones and antihormones","formulations":"Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"H02AB04","source":"who.int"},{"medicine_name":"methylthioninium chloride","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 10 mL ampoule","indication":"Acquired methaemoglobinaemia","combined_with":null,"status":"Added","atc_classification":"V03AB17","source":"who.int"},{"medicine_name":"metoclopramide","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 5 mg per 5 mL\nOral > Solid: 10 mg (hydrochloride)\nParenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A03FA01","source":"who.int"},{"medicine_name":"metoclopramide","eml_section":"Antiemetic medicines","formulations":"Oral > Liquid: 5 mg per 5 mL\nOral > Solid: 10 mg (hydrochloride)\nParenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)","indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"A03FA01","source":"who.int"},{"medicine_name":"metoprolol","eml_section":"Antianginal medicines","formulations":null,"indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"metoprolol","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"metoprolol","eml_section":"Antihypertensive medicines","formulations":null,"indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"metoprolol","eml_section":"Antiarrhythmic medicines","formulations":null,"indication":"Cardiac arrhythmia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritonitis (mild-moderate)","combined_with":"cefotaxime","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritonitis (severe)","combined_with":"cefotaxime","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritonitis (mild-moderate)","combined_with":"ceftriaxone","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritonitis (severe)","combined_with":"ceftriaxone","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritoneal abscess (mild-moderate)","combined_with":"cefotaxime","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritoneal abscess (severe)","combined_with":"cefotaxime","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritoneal abscess (mild-moderate)","combined_with":"ceftriaxone","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritoneal abscess (severe)","combined_with":"ceftriaxone","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Other specified prophylactic measures","combined_with":"cefazolin","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritonitis (mild-moderate)","combined_with":"ciprofloxacin","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Peritoneal abscess (mild-moderate)","combined_with":"ciprofloxacin","status":"Added","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nOral > Solid: 200 to 500 mg tablet\nParenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection\nLocal > Rectal > Suppository: 500 mg suppository; 1 g suppository","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"A01AB17","source":"who.int"},{"medicine_name":"metronidazole","eml_section":"Antiamoebic and antigiardiasis medicines","formulations":"Oral > Liquid: 200 mg per 5 mL (as benzoate)\nParenteral > General injections > unspecified: 500 mg in 100 mL vial\nOral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg","indication":"Amoebiasis","combined_with":null,"status":"Added","atc_classification":"P01AB01","source":"who.int"},{"medicine_name":"micafungin","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection","indication":"Systemic or invasive candidosis","combined_with":null,"status":"Added","atc_classification":"J02AX05","source":"who.int"},{"medicine_name":"miconazole","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Cream: 2% (nitrate)\nLocal > Topical > Ointment: 2% (nitrate)","indication":"Fungal infection of the skin","combined_with":null,"status":"Added","atc_classification":"D01AC02","source":"who.int"},{"medicine_name":"midazolam","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 2 mg per  mL oral liquid\nOral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form\nParenteral > General injections > unspecified: 1 mg per  mL injection; 5 mg per  mL injection","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"N05CD08","source":"who.int"},{"medicine_name":"midazolam","eml_section":"Antiseizure medicines","formulations":"\nParenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)\nLocal > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"midazolam","eml_section":"Antiseizure medicines","formulations":"\nParenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)\nLocal > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N05CD08","source":"who.int"},{"medicine_name":"midazolam","eml_section":"Preoperative medication and sedation for short-term procedures","formulations":"Parenteral > General injections > IV: 1 mg per  mL\nOral > Liquid: 2 mg per  mL\nOral > Solid: 15 mg  tablet; 7.5 mg tablet","indication":"Sedative-hypnotic and anxiolytic drugs","combined_with":null,"status":"Added","atc_classification":"N05CD08","source":"who.int"},{"medicine_name":"mifepristone - misoprostol","eml_section":"Uterotonics","formulations":"Oral > Solid: 200 mg + 200 \u00b5g; 200 mg [1] + 200 \u00b5g [4] in co-package","indication":"Induced abortion","combined_with":null,"status":"Added","atc_classification":"G03XB51","source":"who.int"},{"medicine_name":"miltefosine","eml_section":"Antileishmaniasis medicines","formulations":"Oral > Solid: 10 mg; 50 mg","indication":"Visceral leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CX04","source":"who.int"},{"medicine_name":"miltefosine","eml_section":"Antileishmaniasis medicines","formulations":"Oral > Solid: 10 mg; 50 mg","indication":"Mucocutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CX04","source":"who.int"},{"medicine_name":"miltefosine","eml_section":"Antileishmaniasis medicines","formulations":"Oral > Solid: 10 mg; 50 mg","indication":"Cutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CX04","source":"who.int"},{"medicine_name":"misoprostol","eml_section":"Uterotonics","formulations":"Oral > Solid: 200 \u00b5g\nLocal > Vaginal > tablet: 25 \u00b5g","indication":"Spontaneous abortion, incomplete, without complication","combined_with":null,"status":"Added","atc_classification":"G02AD06","source":"who.int"},{"medicine_name":"misoprostol","eml_section":"Uterotonics","formulations":"Oral > Solid: 200 \u00b5g\nLocal > Vaginal > tablet: 25 \u00b5g","indication":"Unspecified obstetric condition","combined_with":null,"status":"Added","atc_classification":"G02AD06","source":"who.int"},{"medicine_name":"misoprostol","eml_section":"Uterotonics","formulations":"Oral > Solid: 200 \u00b5g\nLocal > Vaginal > tablet: 25 \u00b5g","indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"G02AD06","source":"who.int"},{"medicine_name":"mometasone","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"mometasone + formoterol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"morphine","eml_section":"Preoperative medication and sedation for short-term procedures","formulations":"Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)","indication":"Opioids or related analgesics\u00a0and agents affecting opioid receptors","combined_with":null,"status":"Added","atc_classification":"N02AA01","source":"who.int"},{"medicine_name":"morphine","eml_section":"Opioid analgesics","formulations":"Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)\nOral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)\nOral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)\nParenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)","indication":"Pain","combined_with":null,"status":"Added","atc_classification":"N02AA01","source":"who.int"},{"medicine_name":"moxifloxacin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)\nOral > Solid: 400 mg tablet","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01MA14","source":"who.int"},{"medicine_name":"moxifloxacin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)\nOral > Solid: 400 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01MA14","source":"who.int"},{"medicine_name":"multiple micronutrient powder","eml_section":"Vitamins and minerals","formulations":"Oral > Other: ","indication":"Iron deficiency anaemia","combined_with":null,"status":"Added","atc_classification":"A11AA01","source":"who.int"},{"medicine_name":"multiple micronutrient supplement","eml_section":"Other medicines administered to the mother","formulations":"Tablet containing: \nVit A: 800 mcg retinol activity equivalent\nVit C: 70 mg\nVit D: 5 mcg (200 IU)\nVit E: 10 mg alpha tocopherol equivalent\nVit B1: 1.4 mg\nVit B2: 1.4 mg\nVit B3: 18 mg niacin equivalent\nVit B6: 1.9 mg\nFolic acid: 400 mcg\nVit B12: 2.6 mcg\nIron: 30 mg\nIodine: 150 mcg\nZinc: 15 mg\nSelenium: 65 mcg\nCopper: 2 mg","indication":"Maternal care for other specified conditions predominantly related to pregnancy","combined_with":null,"status":"Added","atc_classification":"A11AA01","source":"who.int"},{"medicine_name":"mumps vaccine","eml_section":"Recommendations for immunization programmes with certain characteristics","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against mumps alone","combined_with":null,"status":"Added","atc_classification":"J07BE01","source":"who.int"},{"medicine_name":"mupirocin","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Cream: 2% (as mupirocin calcium)\nLocal > Topical > Ointment: 2%","indication":"Superficial bacterial folliculitis","combined_with":null,"status":"Added","atc_classification":"D06AX09","source":"who.int"},{"medicine_name":"mupirocin","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Cream: 2% (as mupirocin calcium)\nLocal > Topical > Ointment: 2%","indication":"Impetigo","combined_with":null,"status":"Added","atc_classification":"D06AX09","source":"who.int"},{"medicine_name":"nadroparin","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Acute ischaemic heart disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"nadroparin","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"nalidixic acid","eml_section":"Anti-infective medicines","formulations":"Oral > Solid: 250 mg; 500 mg","indication":"Shigella resistant to unspecified antibiotic","combined_with":null,"status":"Removed","atc_classification":"J01MB02","source":"who.int"},{"medicine_name":"naloxone","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > unspecified: 400 \u00b5g per 1 mL in ampoule (naloxone hydrochloride)","indication":"Unintentional exposure to or harmful effects of opioids or related analgesics","combined_with":null,"status":"Added","atc_classification":"V03AB15","source":"who.int"},{"medicine_name":"natamycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Suspension: 5% eye drops","indication":"Infectious keratitis","combined_with":null,"status":"Added","atc_classification":"S01AA10","source":"who.int"},{"medicine_name":"nelfinavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 250 mg (as mesilate)\nOral > Other: 50 mg per  g oral powder","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AE04","source":"who.int"},{"medicine_name":"neostigmine","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Oral > Solid: 15 mg (neostigmine bromide)\nParenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)","indication":"Myasthenia gravis","combined_with":null,"status":"Added","atc_classification":"N07AA01","source":"who.int"},{"medicine_name":"neostigmine","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Oral > Solid: 15 mg (neostigmine bromide)\nParenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)","indication":"Anticholinesterase reversible","combined_with":null,"status":"Added","atc_classification":"N07AA01","source":"who.int"},{"medicine_name":"netilmicin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"netilmicin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"nevirapine","eml_section":"Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors","formulations":"Oral > Liquid: 50 mg per 5 mL oral solution\nOral > Solid: 200 mg tablet; 50 mg tablet (dispersible)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AG01","source":"who.int"},{"medicine_name":"niclosamide","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid: 500 mg tablet (chewable)","indication":"Hymenolepiasis","combined_with":null,"status":"Added","atc_classification":"P02DA01","source":"who.int"},{"medicine_name":"niclosamide","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid: 500 mg tablet (chewable)","indication":"Diphyllobothriasis","combined_with":null,"status":"Added","atc_classification":"P02DA01","source":"who.int"},{"medicine_name":"niclosamide","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid: 500 mg tablet (chewable)","indication":"Taeniasis due to Taenia saginata","combined_with":null,"status":"Added","atc_classification":"P02DA01","source":"who.int"},{"medicine_name":"niclosamide","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid: 500 mg tablet (chewable)","indication":"Taeniasis due to Taenia solium","combined_with":null,"status":"Added","atc_classification":"P02DA01","source":"who.int"},{"medicine_name":"nicotinamide","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 50 mg","indication":"Pellagra","combined_with":null,"status":"Added","atc_classification":"A11HA01","source":"who.int"},{"medicine_name":"nifedipine","eml_section":"Antioxytocics (tocolytics)","formulations":"Oral > Solid: 10 mg (immediate-release)","indication":"Preterm labour without delivery","combined_with":null,"status":"Added","atc_classification":"C08CA05","source":"who.int"},{"medicine_name":"nifedipine","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 10 mg","indication":"Angina pectoris","combined_with":null,"status":"Removed","atc_classification":"C08CA05","source":"who.int"},{"medicine_name":"nifedipine","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 10 mg tablet; sustained-release formulations","indication":"Essential hypertension","combined_with":null,"status":"Removed","atc_classification":"C08CA05","source":"who.int"},{"medicine_name":"nifurtimox","eml_section":"Medicines for the treatment of 2nd stage African trypanosomiasis","formulations":"Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CC01","source":"who.int"},{"medicine_name":"nifurtimox","eml_section":"American trypanosomiasis","formulations":"Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)","indication":"Chagas disease","combined_with":null,"status":"Added","atc_classification":"P01CC01","source":"who.int"},{"medicine_name":"nilotinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 150 mg capsule; 200 mg capsule","indication":"Chronic myeloid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01EA03","source":"who.int"},{"medicine_name":"nilutamide","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"nitrous oxide","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation: ","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AX13","source":"who.int"},{"medicine_name":"nivolumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Removed","atc_classification":"L01FF01","source":"who.int"},{"medicine_name":"nivolumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion","indication":"Melanoma of skin","combined_with":null,"status":"Added","atc_classification":"L01FF01","source":"who.int"},{"medicine_name":"norethisterone","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 350 \u00b5g","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Removed","atc_classification":"G03AC01","source":"who.int"},{"medicine_name":"norethisterone","eml_section":"Progestogens","formulations":"Oral > Solid: 5 mg\n","indication":"Excessive menstruation with irregular cycle","combined_with":null,"status":"Removed","atc_classification":"G03DC02","source":"who.int"},{"medicine_name":"norethisterone","eml_section":"Progestogens","formulations":"Oral > Solid: 5 mg\n","indication":"Excessive menstruation with irregular cycle","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"norethisterone enantate","eml_section":"Injectable hormonal contraceptives","formulations":"Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule oily solution","indication":"Contact with health services for reasons associated with reproduction","combined_with":null,"status":"Added","atc_classification":"G03AC01","source":"who.int"},{"medicine_name":"normal immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IV: 5% protein solution; 10% protein solution\nParenteral > General injections > IM: 16% protein solution\nParenteral > General injections > SC: 15% protein solution; 16% protein solution","indication":"Primary immunodeficiencies","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"normal immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IV: 5% protein solution; 10% protein solution\nParenteral > General injections > IM: 16% protein solution\nParenteral > General injections > SC: 15% protein solution; 16% protein solution","indication":"Mucocutaneous lymph node syndrome","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"normal immunoglobulin","eml_section":"Human immunoglobulins","formulations":"Parenteral > General injections > IV: 5% protein solution; 10% protein solution\nParenteral > General injections > IM: 16% protein solution\nParenteral > General injections > SC: 15% protein solution; 16% protein solution","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"J06BA02","source":"who.int"},{"medicine_name":"nystatin","eml_section":"Antifungal medicines","formulations":"Oral > Liquid: 100000 IU per  mL\nLocal > Topical > Other: 100000 IU pessary\nOral > Solid > dosage form: 500000 IU\nOral > Solid > lozenge: 100000 IU","indication":"Candidosis","combined_with":null,"status":"Added","atc_classification":"A07AA02","source":"who.int"},{"medicine_name":"ocrelizumab","eml_section":"Medicines for multiple sclerosis","formulations":"Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial\nParenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution","indication":"Relapsing-remitting multiple sclerosis","combined_with":null,"status":"Removed","atc_classification":"L03AX13","source":"who.int"},{"medicine_name":"ocrelizumab","eml_section":"Medicines for multiple sclerosis","formulations":"Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial\nParenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution","indication":"Multiple sclerosis","combined_with":null,"status":"Removed","atc_classification":"L04AA36","source":"who.int"},{"medicine_name":"ofloxacin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 200 mg; 400 mg","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J01MA01","source":"who.int"},{"medicine_name":"ofloxacin","eml_section":"Ear, nose and throat medicines [c]","formulations":null,"indication":"Infectious diseases of external ear","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ofloxacin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.3%","indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"S01AE01","source":"who.int"},{"medicine_name":"ofloxacin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.3%","indication":"Infectious keratitis","combined_with":null,"status":"Added","atc_classification":"S01AE01","source":"who.int"},{"medicine_name":"omadacycline","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 100 mg lyophilized powder for injection\nOral > Solid: 300 mg","indication":"Methicillin resistant Staphylococcus aureus","combined_with":null,"status":"Removed","atc_classification":"J01AA15","source":"who.int"},{"medicine_name":"ombitasvir + paritaprevir + ritonavir","eml_section":"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"J05AP53","source":"who.int"},{"medicine_name":"omeprazole","eml_section":"Antiulcer medicines","formulations":"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid\nOral > Solid: 10 mg; 20 mg; 40 mg\nParenteral > General injections > IV: 40 mg in vial","indication":"Peptic ulcer, site unspecified","combined_with":null,"status":"Added","atc_classification":"A02BC01","source":"who.int"},{"medicine_name":"omeprazole","eml_section":"Antiulcer medicines","formulations":"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid\nOral > Solid: 10 mg; 20 mg; 40 mg\nParenteral > General injections > IV: 40 mg in vial","indication":"Gastro-oesophageal reflux disease","combined_with":null,"status":"Added","atc_classification":"A02BC01","source":"who.int"},{"medicine_name":"omeprazole","eml_section":"Antiulcer medicines","formulations":"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid\nOral > Solid: 10 mg; 20 mg; 40 mg\nParenteral > General injections > IV: 40 mg in vial","indication":"Gastrointestinal bleeding","combined_with":null,"status":"Added","atc_classification":"A02BC01","source":"who.int"},{"medicine_name":"ondansetron","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)\nOral > Liquid: 4 mg per 5 mL (ondansetron base)\nOral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A04AA01","source":"who.int"},{"medicine_name":"ondansetron","eml_section":"Antiemetic medicines","formulations":"Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)\nOral > Liquid: 4 mg per 5 mL (ondansetron base)\nOral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)","indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"A04AA01","source":"who.int"},{"medicine_name":"oral rehydration salts","eml_section":"Oral rehydration","formulations":"Powder for dilution in 200 mL, 500 mL, 1 L:\n\n- glucose 75 mEq\n- sodium 75 mEq or mmol\/L\n- chloride 65 mEq or mmol\/L\n- potassium 20 mEq or mmol\/L\n- citrate 10 mmol\/L\n- osmolarity 245 mOsm\/L\n- glucose 13.5 g\/L\n- sodium chloride 2.6 g\/L\n- potassium chloride 1.5 g\/L\n- trisodium citrate dihydrate 2.9 g\/L","indication":"Diarrhoea","combined_with":null,"status":"Added","atc_classification":"A07CA","source":"who.int"},{"medicine_name":"oral rehydration salts","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Oral","formulations":"Powder for dilution in 200 mL, 500 mL, 1 L:\n\n- glucose 75 mEq\n- sodium 75 mEq or mmol\/L\n- chloride 65 mEq or mmol\/L\n- potassium 20 mEq or mmol\/L\n- citrate 10 mmol\/L\n- osmolarity 245 mOsm\/L\n- glucose 13.5 g\/L\n- sodium chloride 2.6 g\/L\n- potassium chloride 1.5 g\/L\n- trisodium citrate dihydrate 2.9 g\/L","indication":"Other specified disorders of fluid, electrolyte or acid-base balance","combined_with":null,"status":"Added","atc_classification":"A07CA","source":"who.int"},{"medicine_name":"oral rehydration salts - zinc sulfate","eml_section":"Medicines used in diarrhoea","formulations":"Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)","indication":"Diarrhoea","combined_with":null,"status":"Added","atc_classification":"A07CA","source":"who.int"},{"medicine_name":"oseltamivir","eml_section":"Other antivirals","formulations":"Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)","indication":"Influenza due to identified seasonal influenza virus","combined_with":null,"status":"Added","atc_classification":"J05AH02","source":"who.int"},{"medicine_name":"oxaliplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial","indication":"Malignant neoplasm metastasis in large intestine","combined_with":null,"status":"Added","atc_classification":"L01XA03","source":"who.int"},{"medicine_name":"oxaliplatin","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial","indication":"Malignant neoplasms of colon","combined_with":null,"status":"Added","atc_classification":"L01XA03","source":"who.int"},{"medicine_name":"oxamniquine","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Liquid: 250 mg per 5 mL\nOral > Solid: 250 mg capsule","indication":"Schistosomiasis due to Schistosoma mansoni","combined_with":null,"status":"Added","atc_classification":"P02BA02","source":"who.int"},{"medicine_name":"oxazolindinones","eml_section":"Reserve group antibiotics","formulations":".","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxycodone","eml_section":"Opioid analgesics","formulations":null,"indication":"Pain","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxygen","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation: (medical gas)","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"V03AN01","source":"who.int"},{"medicine_name":"oxygen","eml_section":"Medical gases","formulations":"Respiratory > Inhalation: ","indication":"Respiratory failure as acute or chronic","combined_with":null,"status":"Added","atc_classification":"V03AN01","source":"who.int"},{"medicine_name":"oxytetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxytetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious keratitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxytetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxytetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Trachoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"oxytocin","eml_section":"Uterotonics","formulations":"Parenteral > General injections > unspecified: 10 IU per  mL","indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"H01BB02","source":"who.int"},{"medicine_name":"p-aminosalicylate sodium","eml_section":"Antituberculosis medicines","formulations":"Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AA01","source":"who.int"},{"medicine_name":"p-aminosalicylic acid","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 4 g granules in sachet","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AA01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Malignant neoplasms of nasopharynx","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Kaposi sarcoma of unspecified primary site","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Other specified carcinomas of ovary","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"paclitaxel","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 6 mg per  mL","indication":"Malignant neoplasms of cervix uteri","combined_with":null,"status":"Added","atc_classification":"L01CD01","source":"who.int"},{"medicine_name":"palonosetron","eml_section":"Medicines for other common symptoms in palliative care","formulations":null,"indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"palonosetron","eml_section":"Antiemetic medicines","formulations":null,"indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"pancreatic enzymes","eml_section":"Pancreatic enzymes","formulations":"Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.","indication":"Enzyme intestinal","combined_with":null,"status":"Added","atc_classification":"A09AA02","source":"who.int"},{"medicine_name":"paracetamol (acetaminophen)","eml_section":"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","formulations":"Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL\nLocal > Rectal > Suppository: 100 mg; 250 mg\nOral > Solid > dispersible tablet: 100 mg; 250 mg\nOral > Solid > tablet: 250 mg; 325 mg; 500 mg","indication":"Pain","combined_with":null,"status":"Added","atc_classification":"N02BE01","source":"who.int"},{"medicine_name":"paracetamol (acetaminophen)","eml_section":"Antimigraine medicines > For treatment of acute attack","formulations":"Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL\nLocal > Rectal > Suppository: 250 mg\nOral > Solid > dispersible tablet: 100 mg; 250 mg\nOral > Solid > tablet: 250 mg; 325 mg; 500 mg","indication":"Migraine","combined_with":null,"status":"Added","atc_classification":"N02BE01","source":"who.int"},{"medicine_name":"paromomycin","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)","indication":"Visceral leishmaniasis","combined_with":null,"status":"Added","atc_classification":"A07AA06","source":"who.int"},{"medicine_name":"paromomycin","eml_section":"Antiamoebic and antigiardiasis medicines","formulations":"Oral > Liquid: 125 mg per 5 mL as sulfate\nOral > Solid: 250 mg as sulfate","indication":"Amoebiasis","combined_with":null,"status":"Removed","atc_classification":"A07AA06","source":"who.int"},{"medicine_name":"pegaspargase","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01XX24","source":"who.int"},{"medicine_name":"pegylated interferon alfa (2a)","eml_section":"Medicines for hepatitis C > Other antivirals for hepatitis C","formulations":"Parenteral > General injections > SC: 180 \u00b5g in vial; 180 \u00b5g in prefilled syringe","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"L03AB11","source":"who.int"},{"medicine_name":"pegylated interferon alfa (2b)","eml_section":"Medicines for hepatitis C > Other antivirals for hepatitis C","formulations":"Parenteral > General injections > SC: 80 \u00b5g in prefilled syringe; 100 \u00b5g in prefilled syringe","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"L03AB10","source":"who.int"},{"medicine_name":"pembrolizumab","eml_section":"Immunomodulators","formulations":null,"indication":"Melanoma of skin","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"penicillamine","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Oral > Solid: 250 mg","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"M01CC01","source":"who.int"},{"medicine_name":"penicillamine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 250 mg","indication":"Rheumatoid arthritis, serology unspecified","combined_with":null,"status":"Added","atc_classification":"M01CC01","source":"who.int"},{"medicine_name":"pentamidine","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)","indication":"Visceral leishmaniasis","combined_with":null,"status":"Removed","atc_classification":"P01CX01","source":"who.int"},{"medicine_name":"pentamidine","eml_section":"Antipneumocystosis and antitoxoplasmosis medicines","formulations":"Oral > Solid: 200 mg tablet; 300 mg tablet","indication":"Pneumocystosis","combined_with":null,"status":"Added","atc_classification":"P01CX01","source":"who.int"},{"medicine_name":"pentamidine","eml_section":"Medicines for the treatment of 1st stage African trypanosomiasis","formulations":"Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CX01","source":"who.int"},{"medicine_name":"permethrin","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 1%\nLocal > Topical > Cream: 5%","indication":"Pediculosis corporis","combined_with":null,"status":"Added","atc_classification":"P03AC04","source":"who.int"},{"medicine_name":"permethrin","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 1%\nLocal > Topical > Cream: 5%","indication":"Pediculosis capitis","combined_with":null,"status":"Added","atc_classification":"P03AC04","source":"who.int"},{"medicine_name":"permethrin","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Lotion: 1%\nLocal > Topical > Cream: 5%","indication":"Scabies","combined_with":null,"status":"Added","atc_classification":"P03AC04","source":"who.int"},{"medicine_name":"pertussis vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against pertussis alone","combined_with":null,"status":"Added","atc_classification":"J07AJ02","source":"who.int"},{"medicine_name":"pertuzumab","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution","indication":"Carcinoma of breast, specialised type","combined_with":null,"status":"Removed","atc_classification":"L01FD02","source":"who.int"},{"medicine_name":"phenobarbital","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 15 mg per 5 mL\nOral > Solid: 15 to 100 mg\nParenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AA02","source":"who.int"},{"medicine_name":"phenobarbital","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 15 mg per 5 mL\nOral > Solid: 15 to 100 mg\nParenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N03AA02","source":"who.int"},{"medicine_name":"phenoxymethylpenicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid\nOral > Solid: 250 mg (as potassium salt) tablet\nOral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","indication":"Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)","combined_with":null,"status":"Added","atc_classification":"J01CE02","source":"who.int"},{"medicine_name":"phenoxymethylpenicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid\nOral > Solid: 250 mg (as potassium salt) tablet\nOral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","indication":"Periapical abscess without sinus","combined_with":null,"status":"Added","atc_classification":"J01CE02","source":"who.int"},{"medicine_name":"phenoxymethylpenicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid\nOral > Solid: 250 mg (as potassium salt) tablet\nOral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","indication":"Acute pharyngitis","combined_with":null,"status":"Added","atc_classification":"J01CE02","source":"who.int"},{"medicine_name":"phenoxymethylpenicillin","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid\nOral > Solid: 250 mg (as potassium salt) tablet\nOral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01CE02","source":"who.int"},{"medicine_name":"phenytoin","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 30 mg per 5 mL (phenytoin)\nParenteral > General injections > unspecified: 50 mg per  mL in vial (phenytoin sodium)\nOral > Solid > tablet: 50 mg (phenytoin) (chewable)\nOral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AB02","source":"who.int"},{"medicine_name":"phytomenadione","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule\nOral > Solid: 10 mg tablet","indication":"Haemorrhagic disorder due to other specified circulating anticoagulants","combined_with":null,"status":"Added","atc_classification":"B02BA01","source":"who.int"},{"medicine_name":"phytomenadione","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule\nOral > Solid: 10 mg tablet","indication":"Haemorrhagic or haematological disorders of fetus or newborn","combined_with":null,"status":"Added","atc_classification":"B02BA01","source":"who.int"},{"medicine_name":"pilocarpine","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","indication":"Acute angle closure with pupillary block","combined_with":null,"status":"Added","atc_classification":"S01EB01","source":"who.int"},{"medicine_name":"pilocarpine","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","indication":"Ocular hypertension","combined_with":null,"status":"Added","atc_classification":"S01EB01","source":"who.int"},{"medicine_name":"pilocarpine","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"S01EB01","source":"who.int"},{"medicine_name":"piperacillin + tazobactam","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","indication":"Other specified pneumonia (Hospital-acquired pneumonia)","combined_with":null,"status":"Added","atc_classification":"J01CR05","source":"who.int"},{"medicine_name":"piperacillin + tazobactam","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","indication":"Peritonitis (severe)","combined_with":null,"status":"Added","atc_classification":"J01CR05","source":"who.int"},{"medicine_name":"piperacillin + tazobactam","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","indication":"Neutropenia (high-risk)","combined_with":null,"status":"Added","atc_classification":"J01CR05","source":"who.int"},{"medicine_name":"piperacillin + tazobactam","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","indication":"Peritoneal abscess (severe)","combined_with":null,"status":"Added","atc_classification":"J01CR05","source":"who.int"},{"medicine_name":"platelets","eml_section":"Blood and blood components","formulations":"Parenteral > General injections > IV: ","indication":"Blood transfusion without reported diagnosis","combined_with":null,"status":"Added","atc_classification":"B05AX02","source":"who.int"},{"medicine_name":"plazomicin","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","indication":"Carbapenem resistant Acinetobacter baumannii","combined_with":null,"status":"Added","atc_classification":"J01GB14","source":"who.int"},{"medicine_name":"plazomicin","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","indication":"Carbapenem-resistant Pseudomonas aeruginosa","combined_with":null,"status":"Added","atc_classification":"J01GB14","source":"who.int"},{"medicine_name":"plazomicin","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","indication":"Carbapenem resistant Enterobacterales","combined_with":null,"status":"Added","atc_classification":"J01GB14","source":"who.int"},{"medicine_name":"pneumococcal vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against single bacterial diseases","combined_with":null,"status":"Added","atc_classification":"J07AL01","source":"who.int"},{"medicine_name":"podophyllotoxin","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":null,"indication":"Anogenital warts","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"podophyllotoxin","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":null,"indication":"Plantar warts","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"podophyllum resin","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 10 to 25%","indication":"Anogenital warts","combined_with":null,"status":"Added","atc_classification":"D06BB04","source":"who.int"},{"medicine_name":"podophyllum resin","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 10 to 25%","indication":"Plantar warts","combined_with":null,"status":"Added","atc_classification":"D06BB04","source":"who.int"},{"medicine_name":"poliomyelitis vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against poliomyelitis","combined_with":null,"status":"Added","atc_classification":"J07BF01","source":"who.int"},{"medicine_name":"poliomyelitis vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against poliomyelitis","combined_with":null,"status":"Added","atc_classification":"J07BF02","source":"who.int"},{"medicine_name":"poliomyelitis vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against poliomyelitis","combined_with":null,"status":"Added","atc_classification":"J07BF03","source":"who.int"},{"medicine_name":"poliomyelitis vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against poliomyelitis","combined_with":null,"status":"Added","atc_classification":"J07BF04","source":"who.int"},{"medicine_name":"polygeline","eml_section":"Plasma substitutes","formulations":"Parenteral > General injections > IV: 3.5% injectable solution\nParenteral > General injections > IV: 3.5% in solution","indication":"Hypovolaemia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"polygeline","eml_section":"Plasma substitutes","formulations":"Parenteral > General injections > IV: 3.5% injectable solution\nParenteral > General injections > IV: 3.5% in solution","indication":"Hypovolaemia","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"polymyxins","eml_section":"Reserve group antibiotics","formulations":".","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"potassium chloride","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Oral","formulations":"Oral > Liquid: powder for solution","indication":"Hypokalaemia","combined_with":null,"status":"Added","atc_classification":"A12BA01","source":"who.int"},{"medicine_name":"potassium chloride","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol\/mL and Cl- 1.5 mmol\/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol\/mL and Cl- 2 mmol\/mL); 15% solution for dilution (equivalent to K+ 2 mmol\/mL and Cl- 2 mmol\/mL)","indication":"Hypokalaemia","combined_with":null,"status":"Added","atc_classification":"B05XA01","source":"who.int"},{"medicine_name":"potassium ferric hexacyanoferrate","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Oral > Solid: Powder for oral administration","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB31","source":"who.int"},{"medicine_name":"potassium iodide","eml_section":"Antifungal medicines","formulations":"Local > Topical > Solution: Saturated solution","indication":"Sporotrichosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"potassium iodide","eml_section":"Thyroid hormones and antithyroid medicines","formulations":"Oral > Solid: 60 mg","indication":"Thyrotoxicosis","combined_with":null,"status":"Added","atc_classification":"V03AB21","source":"who.int"},{"medicine_name":"potassium permanganate","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Solution: aqueous solution: 1:10 000","indication":"Tropical phagedaenic ulcer","combined_with":null,"status":"Added","atc_classification":"D08AX06","source":"who.int"},{"medicine_name":"potassium permanganate","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Solution: aqueous solution: 1:10 000","indication":"Pemphigus","combined_with":null,"status":"Added","atc_classification":"D08AX06","source":"who.int"},{"medicine_name":"potassium permanganate","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Solution: aqueous solution: 1:10 000","indication":"Other specified pyogenic bacterial infection of skin and subcutaneous tissue","combined_with":null,"status":"Added","atc_classification":"D08AX06","source":"who.int"},{"medicine_name":"potassium permanganate","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Solution: aqueous solution: 1:10 000","indication":"Impetigo","combined_with":null,"status":"Added","atc_classification":"D08AX06","source":"who.int"},{"medicine_name":"povidone iodine","eml_section":"Antiseptics","formulations":"Local > Topical > Solution: 10% (equivalent to 1% available iodine)","indication":"Povidone iodine","combined_with":null,"status":"Added","atc_classification":"D08AG02","source":"who.int"},{"medicine_name":"pralidoxime","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":".","indication":"Exposure to or harmful effects of undetermined intent of pesticides","combined_with":null,"status":"Removed","atc_classification":"V03AB04","source":"who.int"},{"medicine_name":"pramipexole","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 125 \u00b5g immediate-release; 250 mg immediate-release; 500 \u00b5g immediate-release; 750 \u00b5g immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 \u00b5g extended-release; 750 \u00b5g extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BC05","source":"who.int"},{"medicine_name":"pravastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Mixed hyperlipidaemia","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"pravastatin","eml_section":"Lipid-lowering agents","formulations":null,"indication":"Coronary atherosclerosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Paragonimiasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Clonorchiasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Opisthorchiasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Schistosomiasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Taeniasis due to Taenia saginata","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Taeniasis due to Taenia solium","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Diphyllobothriasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Hymenolepiasis","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"praziquantel","eml_section":"Cysticidal medicines","formulations":"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","indication":"Cysticercosis of central nervous system","combined_with":null,"status":"Added","atc_classification":"P02BA01","source":"who.int"},{"medicine_name":"precipitated sulfur","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Ointment: ","indication":"Pthiriasis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"precipitated sulfur","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Ointment: ","indication":"Pediculosis corporis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"precipitated sulfur","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Ointment: ","indication":"Pediculosis capitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"precipitated sulfur","eml_section":"Dermatological medicines > Scabicides and pediculicides","formulations":"Local > Topical > Ointment: ","indication":"Scabies","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Hormones and antihormones","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Anti-inflammatory medicines","formulations":"Local > Rectal > Retention enema: \nLocal > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Anti-inflammatory medicines","formulations":"Local > Rectal > Retention enema: \nLocal > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"A07EA01","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Anti-inflammatory medicines","formulations":"Local > Rectal > Retention enema: \nLocal > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","indication":"Ulcerative colitis","combined_with":null,"status":"Added","atc_classification":"A07EA01","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":"Oral > Liquid: 5 mg per  mL\nOral > Solid: 5 mg; 25 mg","indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"H02AB06","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Ophthalmological preparations > Anti-inflammatory agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)","indication":"Scleritis","combined_with":null,"status":"Added","atc_classification":"S01BA04","source":"who.int"},{"medicine_name":"prednisolone","eml_section":"Ophthalmological preparations > Anti-inflammatory agents","formulations":"Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)","indication":"Anterior uveitis","combined_with":null,"status":"Added","atc_classification":"S01BA04","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Hormones and antihormones","formulations":null,"indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prednisone","eml_section":"Antiallergics and medicines used in anaphylaxis","formulations":null,"indication":"Allergic or hypersensitivity conditions of unspecified type","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"pretomanid","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid > tablet: 200 mg","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK08","source":"who.int"},{"medicine_name":"primaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)","indication":"Malaria due to Plasmodium ovale","combined_with":null,"status":"Added","atc_classification":"P01BA03","source":"who.int"},{"medicine_name":"primaquine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BA03","source":"who.int"},{"medicine_name":"probenecid","eml_section":"Medicines used to treat gout","formulations":"Oral > Solid: 500 mg","indication":"Gout","combined_with":null,"status":"Removed","atc_classification":"M04AB01","source":"who.int"},{"medicine_name":"procainamide","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule (hydrochloride)\nOral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)","indication":"Cardiac arrhythmia","combined_with":null,"status":"Removed","atc_classification":"C01BA02","source":"who.int"},{"medicine_name":"procaine benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection","indication":"Congenital syphilis [children]","combined_with":null,"status":"Added","atc_classification":"J01CE09","source":"who.int"},{"medicine_name":"procaine benzylpenicillin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection","indication":"Syphilis","combined_with":null,"status":"Added","atc_classification":"J01CE09","source":"who.int"},{"medicine_name":"procarbazine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg (as hydrochloride)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01XB01","source":"who.int"},{"medicine_name":"procarbazine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 50 mg (as hydrochloride)","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01XB01","source":"who.int"},{"medicine_name":"progesterone vaginal ring","eml_section":"Intravaginal contraceptives","formulations":"Local > Vaginal > vaginal ring: 2.074 g micronized progesterone","indication":"Contact with health services for contraceptive management","combined_with":null,"status":"Added","atc_classification":"G03DA04","source":"who.int"},{"medicine_name":"proguanil","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 100 mg tablet (hydrochloride)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BB01","source":"who.int"},{"medicine_name":"promethazine","eml_section":"Antiemetic medicines","formulations":"Oral > Liquid: 5 mg per 5 mL (hydrochloride)\nOral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)\nParenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule","indication":"Nausea or vomiting","combined_with":null,"status":"Removed","atc_classification":"R06AD02","source":"who.int"},{"medicine_name":"propanol","eml_section":"Antiseptics","formulations":null,"indication":"Denatured alcohol","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"propofol","eml_section":"General anaesthetics and oxygen > Injectable medicines","formulations":"Parenteral > General injections > IV: 10 mg per  mL; 20 mg per  mL","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AX10","source":"who.int"},{"medicine_name":"propranolol","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","indication":"Essential hypertension","combined_with":null,"status":"Removed","atc_classification":"C07AA05","source":"who.int"},{"medicine_name":"propranolol","eml_section":"Antianginal medicines","formulations":"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)\nOral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","indication":"Angina pectoris","combined_with":null,"status":"Removed","atc_classification":"C07AA05","source":"who.int"},{"medicine_name":"propranolol","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)\nOral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","indication":"Cardiac arrhythmia","combined_with":null,"status":"Removed","atc_classification":"C07AA05","source":"who.int"},{"medicine_name":"propranolol","eml_section":"Antimigraine medicines > For prophylaxis","formulations":"Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)","indication":"Migraine","combined_with":null,"status":"Added","atc_classification":"C07AA05","source":"who.int"},{"medicine_name":"propylthiouracil","eml_section":"Thyroid hormones and antithyroid medicines","formulations":"Oral > Solid: 50 mg","indication":"Thyrotoxicosis","combined_with":null,"status":"Added","atc_classification":"H03BA02","source":"who.int"},{"medicine_name":"prostaglandin e1","eml_section":"Medicines administered to the neonate [c]","formulations":"Parenteral > General injections > IV: 0.5 mg per  mL in alcohol","indication":"Other specified congenital anomaly of great arteries including arterial duct","combined_with":null,"status":"Added","atc_classification":"C01EA01","source":"who.int"},{"medicine_name":"prostaglandin e2","eml_section":"Medicines administered to the neonate [c]","formulations":"Parenteral > General injections > IV: 1 mg per  mL","indication":"Other specified congenital anomaly of great arteries including arterial duct","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"prostaglandin e2","eml_section":"Medicines administered to the neonate [c]","formulations":"Parenteral > General injections > IV: 1 mg per  mL","indication":"Other specified congenital anomaly of great arteries including arterial duct","combined_with":null,"status":"Removed","atc_classification":"G02AD02","source":"who.int"},{"medicine_name":"protamine sulfate","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 5 mL ampoule","indication":"Haemorrhagic disorder due to other specified circulating anticoagulants","combined_with":null,"status":"Added","atc_classification":"V03AB14","source":"who.int"},{"medicine_name":"protionamide","eml_section":"Antituberculosis medicines","formulations":null,"indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"pyrantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","indication":"Ascariasis","combined_with":null,"status":"Added","atc_classification":"P02CC01","source":"who.int"},{"medicine_name":"pyrantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","indication":"Enterobiasis","combined_with":null,"status":"Added","atc_classification":"P02CC01","source":"who.int"},{"medicine_name":"pyrantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","indication":"Trichuriasis","combined_with":null,"status":"Added","atc_classification":"P02CC01","source":"who.int"},{"medicine_name":"pyrantel","eml_section":"Intestinal anthelminthics","formulations":"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","indication":"Hookworm diseases","combined_with":null,"status":"Added","atc_classification":"P02CC01","source":"who.int"},{"medicine_name":"pyrazinamide","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AK01","source":"who.int"},{"medicine_name":"pyridostigmine","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)\nOral > Solid: 60 mg (pyridostigmine bromide)","indication":"Myasthenia gravis","combined_with":null,"status":"Added","atc_classification":"N07AA02","source":"who.int"},{"medicine_name":"pyridoxine","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 25 mg (hydrochloride)","indication":"Vitamin B6 deficiency","combined_with":null,"status":"Added","atc_classification":"A11HA02","source":"who.int"},{"medicine_name":"pyridoxine","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 25 mg (hydrochloride)","indication":"Sideroblastic anaemia","combined_with":null,"status":"Added","atc_classification":"A11HA02","source":"who.int"},{"medicine_name":"pyridoxine","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 25 mg (hydrochloride)","indication":"Other specified polyneuropathy","combined_with":null,"status":"Added","atc_classification":"A11HA02","source":"who.int"},{"medicine_name":"pyrimethamine","eml_section":"Antipneumocystosis and antitoxoplasmosis medicines","formulations":"Oral > Solid: 25 mg","indication":"Toxoplasmosis","combined_with":null,"status":"Added","atc_classification":"P01BD01","source":"who.int"},{"medicine_name":"quinidine","eml_section":"Antiarrhythmic medicines","formulations":"Oral > Solid: 200 mg (sulfate)","indication":"Cardiac arrhythmia","combined_with":null,"status":"Removed","atc_classification":"C01BA01","source":"who.int"},{"medicine_name":"quinine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Parenteral > General injections > IV: 300 mg per  mL in 2 mL ampoule (quinine hydrochloride)\nOral > Solid: 300 mg (quinine sulfate or quinine bisulfate)","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BC01","source":"who.int"},{"medicine_name":"rabies vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against rabies","combined_with":null,"status":"Added","atc_classification":"J07BG01","source":"who.int"},{"medicine_name":"raltegravir","eml_section":"Antiretrovirals > Integrase inhibitors","formulations":"Oral > Liquid: 100 mg granules for oral suspension\nOral > Solid: 400 mg tablet; 25 mg tablet (chewable)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AJ01","source":"who.int"},{"medicine_name":"ranibizumab","eml_section":"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","formulations":".","indication":"Retinal venous occlusions","combined_with":null,"status":"Removed","atc_classification":"S01LA04","source":"who.int"},{"medicine_name":"ranibizumab","eml_section":"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","formulations":".","indication":"Diabetic macular oedema","combined_with":null,"status":"Removed","atc_classification":"S01LA04","source":"who.int"},{"medicine_name":"ranibizumab","eml_section":"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","formulations":".","indication":"Degenerative high myopia","combined_with":null,"status":"Removed","atc_classification":"S01LA04","source":"who.int"},{"medicine_name":"ranibizumab","eml_section":"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","formulations":".","indication":"Age related macular degeneration","combined_with":null,"status":"Removed","atc_classification":"S01LA04","source":"who.int"},{"medicine_name":"ranitidine","eml_section":"Antiulcer medicines","formulations":"Oral > Liquid: 75 mg per 5 mL (as hydrochloride)\nOral > Solid: 150 mg (as hydrochloride)\nParenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)","indication":"Gastro-oesophageal reflux disease","combined_with":null,"status":"Added","atc_classification":"A02BA02","source":"who.int"},{"medicine_name":"ranitidine","eml_section":"Antiulcer medicines","formulations":"Oral > Liquid: 75 mg per 5 mL (as hydrochloride)\nOral > Solid: 150 mg (as hydrochloride)\nParenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)","indication":"Peptic ulcer, site unspecified","combined_with":null,"status":"Added","atc_classification":"A02BA02","source":"who.int"},{"medicine_name":"rasburicase","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution","indication":"Tumour lysis syndrome","combined_with":null,"status":"Added","atc_classification":"V03AF07","source":"who.int"},{"medicine_name":"ravidasvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid > tablet: 200 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"realgar-indigo naturalis formulation","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)","indication":"Acute myeloid leukaemia with recurrent genetic abnormalities","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"red blood cells","eml_section":"Blood and blood components","formulations":"Parenteral > General injections > IV: ","indication":"Blood transfusion without reported diagnosis","combined_with":null,"status":"Added","atc_classification":"B05AX01","source":"who.int"},{"medicine_name":"retinol","eml_section":"Vitamins and minerals","formulations":"Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection\nOral > Liquid: 100000 IU per  mL (as palmitate) oral oily solution in multidose dispenser\nOral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule","indication":"Vitamin A deficiency","combined_with":null,"status":"Added","atc_classification":"A11CA01","source":"who.int"},{"medicine_name":"ribavirin","eml_section":"Other antivirals","formulations":"Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution\nOral > Solid: 200 mg; 400 mg; 600 mg","indication":"Viral haemorrhagic fever, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"J05AB04","source":"who.int"},{"medicine_name":"ribavirin","eml_section":"Medicines for hepatitis C > Other antivirals for hepatitis C","formulations":"Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution\nOral > Solid: 200 mg; 400 mg; 600 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP01","source":"who.int"},{"medicine_name":"riboflavin","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 5 mg","indication":"Vitamin B2 deficiency","combined_with":null,"status":"Added","atc_classification":"A11HA04","source":"who.int"},{"medicine_name":"rifabutin","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 150 mg","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB04","source":"who.int"},{"medicine_name":"rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Liquid: 20 mg per  mL\nOral > Solid: 150 mg; 300 mg\nParenteral > General injections > IV: 600 mg in vial powder for injection","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB02","source":"who.int"},{"medicine_name":"rifampicin","eml_section":"Antituberculosis medicines","formulations":"Oral > Liquid: 20 mg per  mL\nOral > Solid: 150 mg; 300 mg\nParenteral > General injections > IV: 600 mg in vial powder for injection","indication":"Other specified tuberculosis","combined_with":null,"status":"Removed","atc_classification":"J04AB02","source":"who.int"},{"medicine_name":"rifampicin","eml_section":"Antileprosy medicines","formulations":"Oral > Liquid: 20 mg per  mL\nOral > Solid: 150 mg; 300 mg","indication":"Leprosy","combined_with":null,"status":"Added","atc_classification":"J04AB02","source":"who.int"},{"medicine_name":"rifapentine","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 150 mg tablet; 300 mg tablet","indication":"Tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB05","source":"who.int"},{"medicine_name":"rifapentine","eml_section":"Antituberculosis medicines","formulations":"Oral > Solid: 150 mg tablet; 300 mg tablet","indication":"Latent tuberculosis","combined_with":null,"status":"Added","atc_classification":"J04AB05","source":"who.int"},{"medicine_name":"risdiplam","eml_section":"Medicines for diseases of the nervous system","formulations":"Oral > Liquid: 0.75 mg per  mL powder for oral liquid","indication":"Spinal muscular atrophy","combined_with":null,"status":"Removed","atc_classification":"M09AX10","source":"who.int"},{"medicine_name":"ritonavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AE03","source":"who.int"},{"medicine_name":"rituximab","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"L01FA01","source":"who.int"},{"medicine_name":"rituximab","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","indication":"Chronic lymphocytic leukaemia or small lymphocytic lymphoma","combined_with":null,"status":"Added","atc_classification":"L01FA01","source":"who.int"},{"medicine_name":"rituximab","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"L01FA01","source":"who.int"},{"medicine_name":"rituximab","eml_section":"Medicines for multiple sclerosis","formulations":"Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial","indication":"Multiple sclerosis","combined_with":null,"status":"Added","atc_classification":"L01FA01","source":"who.int"},{"medicine_name":"rivaroxaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"rivaroxaban","eml_section":"Medicines affecting coagulation","formulations":null,"indication":"Other specified atrial fibrillation","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"ropinirole","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04BC04","source":"who.int"},{"medicine_name":"rotavirus vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BH01","source":"who.int"},{"medicine_name":"rotavirus vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BH02","source":"who.int"},{"medicine_name":"rubella vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against rubella alone","combined_with":null,"status":"Added","atc_classification":"J07BJ01","source":"who.int"},{"medicine_name":"salbutamol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Parenteral > General injections > IV: 50 \u00b5g per  mL in 5 mL ampoule (as sulfate)\nRespiratory > Inhalation > aerosol: 100 \u00b5g per  dose (as sulfate); 100 \u00b5g per  dose (as sulfate) metered-dose inhaler\nRespiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers","indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"R03AC02","source":"who.int"},{"medicine_name":"salbutamol","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Parenteral > General injections > IV: 50 \u00b5g per  mL in 5 mL ampoule (as sulfate)\nRespiratory > Inhalation > aerosol: 100 \u00b5g per  dose (as sulfate); 100 \u00b5g per  dose (as sulfate) metered-dose inhaler\nRespiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers","indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"R03AC02","source":"who.int"},{"medicine_name":"salicylic acid","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 5%","indication":"Seborrhoeic dermatitis","combined_with":null,"status":"Added","atc_classification":"D01AE12","source":"who.int"},{"medicine_name":"salicylic acid","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 5%","indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"D01AE12","source":"who.int"},{"medicine_name":"salicylic acid","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Solution: 5%","indication":"Ichthyoses","combined_with":null,"status":"Added","atc_classification":"D01AE12","source":"who.int"},{"medicine_name":"saquinavir","eml_section":"Antiretrovirals > Protease inhibitors","formulations":"Oral > Solid: 200 mg; 500 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AE01","source":"who.int"},{"medicine_name":"selenium sulfide","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Suspension: 2% detergent-based","indication":"Seborrhoeic dermatitis","combined_with":null,"status":"Added","atc_classification":"D01AE13","source":"who.int"},{"medicine_name":"selenium sulfide","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Suspension: 2% detergent-based","indication":"Pityriasis versicolor","combined_with":null,"status":"Added","atc_classification":"D01AE13","source":"who.int"},{"medicine_name":"senna","eml_section":"Medicines for other common symptoms in palliative care","formulations":"Oral > Liquid: 7.5 mg per 5 mL oral liquid","indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"A06AB06","source":"who.int"},{"medicine_name":"senna","eml_section":"Laxatives","formulations":"Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)","indication":"Constipation","combined_with":null,"status":"Added","atc_classification":"A06AB06","source":"who.int"},{"medicine_name":"sevoflurane","eml_section":"General anaesthetics and oxygen > Inhalational medicines","formulations":"Respiratory > Inhalation > liquid: ","indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"N01AB08","source":"who.int"},{"medicine_name":"silver diamine fluoride","eml_section":"Dental medicines and preparations","formulations":"Local > Dental > Solution: 38% w\/v","indication":"Dental caries","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"silver nitrate","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Solution (eye drops): 1%","indication":"Neonatal conjunctivitis or dacryocystitis","combined_with":null,"status":"Removed","atc_classification":"D08AL01","source":"who.int"},{"medicine_name":"silver sulfadiazine","eml_section":"Dermatological medicines > Anti-infective medicines","formulations":"Local > Topical > Cream: 1%","indication":"Burns","combined_with":null,"status":"Added","atc_classification":"D06BA01","source":"who.int"},{"medicine_name":"simeprevir","eml_section":"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 150 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Removed","atc_classification":"J05AP05","source":"who.int"},{"medicine_name":"simvastatin","eml_section":"Lipid-lowering agents","formulations":"Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg","indication":"Mixed hyperlipidaemia","combined_with":null,"status":"Added","atc_classification":"C10AA01","source":"who.int"},{"medicine_name":"simvastatin","eml_section":"Lipid-lowering agents","formulations":"Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg","indication":"Coronary atherosclerosis","combined_with":null,"status":"Added","atc_classification":"C10AA01","source":"who.int"},{"medicine_name":"simvastatin","eml_section":"Medicines for endocrine disorders","formulations":"Oral > Solid: 20 mg","indication":"Polycystic ovary syndrome","combined_with":null,"status":"Removed","atc_classification":"C10AA01","source":"who.int"},{"medicine_name":"smallpox vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Removed","atc_classification":"J07BX01","source":"who.int"},{"medicine_name":"snake antivenom","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":".","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Removed","atc_classification":"J06AA03","source":"who.int"},{"medicine_name":"sodium calcium edetate","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 200 mg per  mL in 5 mL ampoule","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB03","source":"who.int"},{"medicine_name":"sodium chloride","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol\/L and Cl- 154 mmol\/L)","indication":"Other specified disorders of fluid, electrolyte or acid-base balance","combined_with":null,"status":"Added","atc_classification":"B05XA03","source":"who.int"},{"medicine_name":"sodium hydrogen carbonate","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","formulations":"Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol\/L and HCO3- 167 mmol\/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol\/L and HCO3- 1000 mmol\/L)","indication":"Acidosis","combined_with":null,"status":"Added","atc_classification":"B05XA02","source":"who.int"},{"medicine_name":"sodium nitrite","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 30 mg per  mL in 10 mL ampoule","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB08","source":"who.int"},{"medicine_name":"sodium nitroprusside","eml_section":"Antihypertensive medicines","formulations":"Parenteral > General injections > IV: 50 mg in ampoule powder for infusion","indication":"Hypertensive crisis","combined_with":null,"status":"Added","atc_classification":"C02DD01","source":"who.int"},{"medicine_name":"sodium stibogluconate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","indication":"Visceral leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB02","source":"who.int"},{"medicine_name":"sodium stibogluconate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","indication":"Mucocutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB02","source":"who.int"},{"medicine_name":"sodium stibogluconate","eml_section":"Antileishmaniasis medicines","formulations":"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","indication":"Cutaneous leishmaniasis","combined_with":null,"status":"Added","atc_classification":"P01CB02","source":"who.int"},{"medicine_name":"sodium thiosulfate","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Solution: 15%","indication":"Pityriasis versicolor","combined_with":null,"status":"Added","atc_classification":"V03AB06","source":"who.int"},{"medicine_name":"sodium thiosulfate","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Parenteral > General injections > IV: 250 mg per  mL in 50 mL ampoule","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"V03AB06","source":"who.int"},{"medicine_name":"sofosbuvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 400 mg; 200 mg","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP08","source":"who.int"},{"medicine_name":"sofosbuvir + velpatasvir","eml_section":"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","formulations":"Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet","indication":"Chronic hepatitis C","combined_with":null,"status":"Added","atc_classification":"J05AP55","source":"who.int"},{"medicine_name":"spectinomycin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection","indication":"Gonococcal infection","combined_with":null,"status":"Added","atc_classification":"J01XX04","source":"who.int"},{"medicine_name":"spectinomycin","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01XX04","source":"who.int"},{"medicine_name":"spironolactone","eml_section":"Medicines used in heart failure","formulations":"Oral > Solid: 25 mg","indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"C03DA01","source":"who.int"},{"medicine_name":"spironolactone","eml_section":"Diuretics","formulations":"Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL\nOral > Solid: 25 mg","indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"C03DA01","source":"who.int"},{"medicine_name":"spironolactone","eml_section":"Diuretics","formulations":"Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL\nOral > Solid: 25 mg","indication":"Ascites","combined_with":null,"status":"Added","atc_classification":"C03DA01","source":"who.int"},{"medicine_name":"stavudine","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Liquid: 5 mg per 5 mL powder for oral solution\nOral > Solid: 15 mg; 20 mg; 30 mg","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Removed","atc_classification":"J05AF04","source":"who.int"},{"medicine_name":"streptokinase","eml_section":"Thrombolytic medicines","formulations":"Parenteral > General injections > IV: 1.5 million IU in vial powder for injection","indication":"Acute myocardial infarction","combined_with":null,"status":"Added","atc_classification":"B01AD01","source":"who.int"},{"medicine_name":"streptomycin (injection)","eml_section":"Antituberculosis medicines","formulations":"Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial","indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"J01GA01","source":"who.int"},{"medicine_name":"succimer","eml_section":"Antidotes and other substances used in poisonings > Specific","formulations":"Oral > Solid: 100 mg","indication":"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"sulfacetamide","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 10% (sodium salt)","indication":"Other specified conjunctivitis","combined_with":null,"status":"Removed","atc_classification":"S01AB04","source":"who.int"},{"medicine_name":"sulfadiazine","eml_section":"Antipneumocystosis and antitoxoplasmosis medicines","formulations":"Oral > Solid: 500 mg","indication":"Toxoplasmosis","combined_with":null,"status":"Added","atc_classification":"J01EC02","source":"who.int"},{"medicine_name":"sulfadiazine","eml_section":"Anti-infective medicines","formulations":"Oral > Solid: 500 mg\nParenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01EC02","source":"who.int"},{"medicine_name":"sulfadimidine","eml_section":"Anti-infective medicines","formulations":"Oral > Liquid: 500 mg per 5 mL\nOral > Solid: 500 mg\nParenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01EB03","source":"who.int"},{"medicine_name":"sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 500 mg + 25 mg tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BD51","source":"who.int"},{"medicine_name":"sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For curative treatment","formulations":"Oral > Solid: 500 mg + 25 mg tablet","indication":"Malaria due to Plasmodium vivax","combined_with":null,"status":"Added","atc_classification":"P01BD51","source":"who.int"},{"medicine_name":"sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 500 mg + 25 mg tablet\nOral > Solid: 250 mg + 12.5 mg tablet","indication":"Malaria due to Plasmodium falciparum","combined_with":null,"status":"Added","atc_classification":"P01BD51","source":"who.int"},{"medicine_name":"sulfadoxine + pyrimethamine","eml_section":"Antimalarial medicines > For chemoprevention","formulations":"Oral > Solid: 500 mg + 25 mg tablet\nOral > Solid: 250 mg + 12.5 mg tablet","indication":"Malaria","combined_with":null,"status":"Added","atc_classification":"P01BD51","source":"who.int"},{"medicine_name":"sulfamethoxazole + trimethoprim","eml_section":"Access group antibiotics","formulations":"Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 10 mL ampoule; 80 mg + 16 mg per  mL in 5 mL ampoule\nOral > Liquid: 200 mg + 40 mg per 5 mL oral liquid\nOral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01EE01","source":"who.int"},{"medicine_name":"sulfamethoxazole + trimethoprim","eml_section":"Antipneumocystosis and antitoxoplasmosis medicines","formulations":"Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 5 mL ampoule; 80 mg + 16 mg per  mL in 10 mL ampoule\nOral > Liquid: 200 mg + 40 mg per 5 mL oral liquid\nOral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet\nOral > Solid > dispersible tablet: 100 mg + 20 mg","indication":"Pneumocystosis","combined_with":null,"status":"Added","atc_classification":"J01EE01","source":"who.int"},{"medicine_name":"sulfasalazine","eml_section":"Disease-modifying anti-rheumatic drugs (DMARDs)","formulations":"Oral > Solid: 500 mg","indication":"Rheumatoid arthritis, serology unspecified","combined_with":null,"status":"Added","atc_classification":"A07EC01","source":"who.int"},{"medicine_name":"sulfasalazine","eml_section":"Anti-inflammatory medicines","formulations":"Oral > Solid: 500 mg\nLocal > Rectal > Suppository: 500 mg\nLocal > Rectal > Retention enema: ","indication":"Crohn disease site","combined_with":null,"status":"Added","atc_classification":"A07EC01","source":"who.int"},{"medicine_name":"sulfasalazine","eml_section":"Anti-inflammatory medicines","formulations":"Oral > Solid: 500 mg\nLocal > Rectal > Suppository: 500 mg\nLocal > Rectal > Retention enema: ","indication":"Ulcerative colitis","combined_with":null,"status":"Added","atc_classification":"A07EC01","source":"who.int"},{"medicine_name":"sumatriptan","eml_section":"Antimigraine medicines > For treatment of acute attack","formulations":"Oral > Solid: 50 mg","indication":"Migraine","combined_with":null,"status":"Added","atc_classification":"N02CC01","source":"who.int"},{"medicine_name":"suramin sodium","eml_section":"Antifilarials","formulations":"Parenteral > General injections > IV: 1 g in vial","indication":"Filariasis","combined_with":null,"status":"Removed","atc_classification":"P01CX02","source":"who.int"},{"medicine_name":"suramin sodium","eml_section":"Medicines for the treatment of 1st stage African trypanosomiasis","formulations":"Parenteral > General injections > IV: 1 g in vial","indication":"African trypanosomiasis","combined_with":null,"status":"Added","atc_classification":"P01CX02","source":"who.int"},{"medicine_name":"surfactant","eml_section":"Medicines administered to the neonate [c]","formulations":"Respiratory > Suspension: 80 mg per  mL for intratracheal instillation; 25 mg per  mL for intratracheal instillation","indication":"Respiratory distress syndrome of newborn","combined_with":null,"status":"Added","atc_classification":"R07AA02","source":"who.int"},{"medicine_name":"suxamethonium","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 50 mg per  mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial","indication":"Muscle relaxants","combined_with":null,"status":"Added","atc_classification":"M03AB01","source":"who.int"},{"medicine_name":"tacalcitol","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":null,"indication":"Psoriasis of unspecified type","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tacrolimus","eml_section":"Immunomodulators for non-malignant disease","formulations":"Parenteral > General injections > IV: 5 mg per  mL in 1 mL vial\nOral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension\nOral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)","indication":"Failure or rejection of transplanted organs or tissues","combined_with":null,"status":"Added","atc_classification":"L04AD02","source":"who.int"},{"medicine_name":"tamoxifen","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L02BA01","source":"who.int"},{"medicine_name":"tamoxifen","eml_section":"Hormones and antihormones","formulations":"Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)","indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L02BA01","source":"who.int"},{"medicine_name":"telmisartan + amlodipine","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09DB04","source":"who.int"},{"medicine_name":"telmisartan + hydrochlorothiazide","eml_section":"Antihypertensive medicines","formulations":"Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg","indication":"Essential hypertension","combined_with":null,"status":"Added","atc_classification":"C09DA07","source":"who.int"},{"medicine_name":"tenofovir alafenamide","eml_section":"Medicines for hepatitis B > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Solid: 25 mg","indication":"Chronic hepatitis B","combined_with":null,"status":"Removed","atc_classification":"J05AF13","source":"who.int"},{"medicine_name":"tenofovir disoproxil fumarate","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AF07","source":"who.int"},{"medicine_name":"tenofovir disoproxil fumarate","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","indication":"Contact with or exposure to human immunodeficiency virus","combined_with":null,"status":"Added","atc_classification":"J05AF07","source":"who.int"},{"medicine_name":"tenofovir disoproxil fumarate","eml_section":"Medicines for hepatitis B > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","indication":"Chronic hepatitis B","combined_with":null,"status":"Added","atc_classification":"J05AF07","source":"who.int"},{"medicine_name":"terbinafine","eml_section":"Dermatological medicines > Antifungal medicines","formulations":"Local > Topical > Cream: 1% terbinafine hydrochloride\nLocal > Topical > Ointment: 1% terbinafine hydrochloride","indication":"Fungal infection of the skin","combined_with":null,"status":"Added","atc_classification":"D01AE15","source":"who.int"},{"medicine_name":"terbutaline","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"terbutaline","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Asthma","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"terizidone","eml_section":"Antituberculosis medicines","formulations":null,"indication":"Multi-drug resistant Mycobacterium tuberculosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"testosterone","eml_section":"Androgens","formulations":"Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule (enantate)","indication":"Testicular dysfunction or testosterone-related disorders","combined_with":null,"status":"Added","atc_classification":"G03BA03","source":"who.int"},{"medicine_name":"tetanus antitoxin","eml_section":"Immunologicals > Sera, immunoglobulins and monoclonal antibodies","formulations":"Parenteral > General injections > IM: 50000 IU in vial","indication":"Tetanus","combined_with":null,"status":"Removed","atc_classification":"J06AA02","source":"who.int"},{"medicine_name":"tetanus vaccine","eml_section":"Recommendations for all immunization programmes","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against tetanus alone","combined_with":null,"status":"Added","atc_classification":"J07AM01","source":"who.int"},{"medicine_name":"tetracaine","eml_section":"Ophthalmological preparations > Local anaesthetics","formulations":"Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)","indication":"Local anaesthetics","combined_with":null,"status":"Added","atc_classification":"S01HA03","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Access group antibiotics","formulations":"Oral > Solid: 250 mg (hydrochloride)","indication":"Bacterial infection of unspecified site","combined_with":null,"status":"Removed","atc_classification":"J01AA07","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","indication":"Neonatal conjunctivitis or dacryocystitis","combined_with":null,"status":"Removed","atc_classification":"S01AA09","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"S01AA09","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","indication":"Infectious keratitis","combined_with":null,"status":"Added","atc_classification":"S01AA09","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"S01AA09","source":"who.int"},{"medicine_name":"tetracycline","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","indication":"Trachoma","combined_with":null,"status":"Added","atc_classification":"S01AA09","source":"who.int"},{"medicine_name":"thalidomide","eml_section":"Immunomodulators","formulations":"Oral > Solid: 50 mg","indication":"Plasma cell myeloma","combined_with":null,"status":"Added","atc_classification":"L04AX02","source":"who.int"},{"medicine_name":"thiamine","eml_section":"Vitamins and minerals","formulations":"Oral > Solid: 50 mg (hydrochloride)","indication":"Vitamin B1 deficiency","combined_with":null,"status":"Added","atc_classification":"A11DA01","source":"who.int"},{"medicine_name":"thiopental","eml_section":"General anaesthetics and oxygen > Injectable medicines","formulations":null,"indication":"Anaesthetics and therapeutic gases","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tick-borne encephalitis vaccine","eml_section":"Recommendations for certain regions","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against arthropod-borne viral encephalitis","combined_with":null,"status":"Added","atc_classification":"J07BA01","source":"who.int"},{"medicine_name":"tigecycline","eml_section":"Reserve group antibiotics","formulations":"Parenteral > General injections > IV: 50 mg in vial powder for injection","indication":"Other specified bacterial diseases","combined_with":null,"status":"Removed","atc_classification":"J01AA12","source":"who.int"},{"medicine_name":"timolol","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)","indication":"Primary open-angle glaucoma","combined_with":null,"status":"Added","atc_classification":"S01ED01","source":"who.int"},{"medicine_name":"timolol","eml_section":"Ophthalmological preparations > Miotics and antiglaucoma medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)","indication":"Ocular hypertension","combined_with":null,"status":"Added","atc_classification":"S01ED01","source":"who.int"},{"medicine_name":"tinidazole","eml_section":"Antiamoebic and antigiardiasis medicines","formulations":null,"indication":"Amoebiasis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tioguanine","eml_section":"Cytotoxic medicines","formulations":"Oral > Solid: 40 mg","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01BB03","source":"who.int"},{"medicine_name":"tiotropium bromide","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":"Respiratory > Inhalation > dry powder: 18 \u00b5g capsule\nRespiratory > Inhalation > solution: 1.25 \u00b5g per  actuation; 2.5 \u00b5g per  actuation","indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"R03BB04","source":"who.int"},{"medicine_name":"tisagenlecleucel","eml_section":"Antineoplastics and supportive medicines","formulations":null,"indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"tislelizumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 100 mg per 10 mL","indication":"Malignant neoplasms of urinary tract","combined_with":null,"status":"Removed","atc_classification":"L01FF09","source":"who.int"},{"medicine_name":"tislelizumab","eml_section":"Immunomodulators","formulations":"Parenteral > General injections > IV: 100 mg per 10 mL","indication":"Hodgkin lymphoma","combined_with":null,"status":"Removed","atc_classification":"L01FF09","source":"who.int"},{"medicine_name":"tobramycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Other specified conjunctivitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tobramycin","eml_section":"Ophthalmological preparations > Anti-infective agents","formulations":null,"indication":"Infectious blepharitis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tolbutamide","eml_section":"Oral hypoglycaemic agents","formulations":"Oral > Solid: 500 mg","indication":"Type 2 diabetes mellitus","combined_with":null,"status":"Removed","atc_classification":"A10BB03","source":"who.int"},{"medicine_name":"torasemide","eml_section":"Medicines used in heart failure","formulations":null,"indication":"Heart failure","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"torasemide","eml_section":"Diuretics","formulations":null,"indication":"Anuria or oliguria","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"torasemide","eml_section":"Diuretics","formulations":null,"indication":"Oedema","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tramadol","eml_section":"Opioid analgesics","formulations":"Oral > Liquid: 100 mg per  mL (hydrochloride)\nOral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release\nParenteral > General injections > unspecified: 50 mg per  mL in 2 mL ampoule (hydrochloride)","indication":"Chronic cancer pain","combined_with":null,"status":"Removed","atc_classification":"N02AX02","source":"who.int"},{"medicine_name":"trametinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 0.5 mg; 2 mg","indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"L01EE01","source":"who.int"},{"medicine_name":"tranexamic acid","eml_section":"Medicines affecting coagulation","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","indication":"Haemorrhage, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"B02AA02","source":"who.int"},{"medicine_name":"tranexamic acid","eml_section":"Other medicines administered to the mother","formulations":"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","indication":"Postpartum haemorrhage","combined_with":null,"status":"Added","atc_classification":"B02AA02","source":"who.int"},{"medicine_name":"trastuzumab","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection","indication":"Carcinoma of breast, specialised type","combined_with":null,"status":"Added","atc_classification":"L01FD01","source":"who.int"},{"medicine_name":"trastuzumab emtansine","eml_section":"Targeted therapies","formulations":"Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection","indication":"Carcinoma of breast, specialised type","combined_with":null,"status":"Removed","atc_classification":"L01FD03","source":"who.int"},{"medicine_name":"triclabendazole","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 250 mg (scored)","indication":"Fascioliasis","combined_with":null,"status":"Added","atc_classification":"P02BX04","source":"who.int"},{"medicine_name":"triclabendazole","eml_section":"Antischistosomals and other antitrematode medicines","formulations":"Oral > Solid > tablet: 250 mg (scored)","indication":"Paragonimiasis","combined_with":null,"status":"Added","atc_classification":"P02BX04","source":"who.int"},{"medicine_name":"trihexyphenidyl","eml_section":"Antiseizure medicines","formulations":"Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)","indication":"Parkinson disease","combined_with":null,"status":"Removed","atc_classification":"N04AA01","source":"who.int"},{"medicine_name":"trihexyphenidyl","eml_section":"Medicines for parkinsonism","formulations":null,"indication":"Parkinson disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"trimethoprim","eml_section":"Access group antibiotics","formulations":"Oral > Liquid: 50 mg per  mL\nOral > Solid: 100 mg; 200 mg","indication":"Infectious cystitis","combined_with":null,"status":"Added","atc_classification":"J01EA01","source":"who.int"},{"medicine_name":"triptorelin","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"triptorelin","eml_section":"Hormones and antihormones","formulations":null,"indication":"Malignant neoplasms of prostate","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tropicamide","eml_section":"Diagnostic agents > Ophthalmic medicines","formulations":"Local > Ophthalmological > Solution (eye drops): 0.5%","indication":"Cycloplegic drug","combined_with":null,"status":"Added","atc_classification":"S01FA06","source":"who.int"},{"medicine_name":"tropisetron","eml_section":"Medicines for other common symptoms in palliative care","formulations":null,"indication":"Palliative care","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tropisetron","eml_section":"Antiemetic medicines","formulations":null,"indication":"Nausea or vomiting","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"tuberculin, purified protein derivative","eml_section":"Immunologicals > Diagnostic agents","formulations":"Parenteral > Locoregional injections > Intradermal: ","indication":"Mycobacterial diseases","combined_with":null,"status":"Added","atc_classification":"V04CF01","source":"who.int"},{"medicine_name":"tubocurarine","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 1.5 mL ampoule (tubocurarine chloride)","indication":"Muscle relaxants","combined_with":null,"status":"Removed","atc_classification":"M03AA02","source":"who.int"},{"medicine_name":"typhoid vaccine","eml_section":"Recommendations for some high-risk populations","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against typhoid-paratyphoid alone","combined_with":null,"status":"Added","atc_classification":"J07AP03","source":"who.int"},{"medicine_name":"ulipristal","eml_section":"Oral hormonal contraceptives","formulations":"Oral > Solid: 30 mg tablet (ulipristal acetate)","indication":"Contact with health services for postcoital contraception","combined_with":null,"status":"Added","atc_classification":"G03AD02","source":"who.int"},{"medicine_name":"umeclidinium","eml_section":"Antiasthmatic and medicines for chronic obstructive pulmonary disease","formulations":null,"indication":"Chronic obstructive pulmonary disease","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"urea","eml_section":"Dermatological medicines > Medicines affecting skin differentiation and proliferation","formulations":"Local > Topical > Cream: 10%; 5%\nLocal > Topical > Ointment: 10%; 5%","indication":"Xerosis cutis or asteatosis","combined_with":null,"status":"Added","atc_classification":"D02AE01","source":"who.int"},{"medicine_name":"valaciclovir","eml_section":"Antiherpes medicines","formulations":null,"indication":"Zoster","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"valaciclovir","eml_section":"Antiherpes medicines","formulations":null,"indication":"Varicella","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"valaciclovir","eml_section":"Antiherpes medicines","formulations":null,"indication":"Herpes simplex infections","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"valganciclovir","eml_section":"Other antivirals","formulations":"Oral > Liquid: 50 mg per  mL powder for oral solution\nOral > Solid: 450 mg Tablet","indication":"Cytomegaloviral retinitis","combined_with":null,"status":"Added","atc_classification":"J05AB14","source":"who.int"},{"medicine_name":"valproic acid (sodium valproate)","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 200 mg per 5 mL\nOral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)\nParenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule","indication":"Epilepsy or seizures","combined_with":null,"status":"Added","atc_classification":"N03AG01","source":"who.int"},{"medicine_name":"valproic acid (sodium valproate)","eml_section":"Antiseizure medicines","formulations":"Oral > Liquid: 200 mg per 5 mL\nOral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)\nParenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule","indication":"Status epilepticus","combined_with":null,"status":"Added","atc_classification":"N03AG01","source":"who.int"},{"medicine_name":"valproic acid (sodium valproate)","eml_section":"Medicines for bipolar disorders","formulations":"Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)","indication":"Bipolar or related disorders","combined_with":null,"status":"Added","atc_classification":"N03AG01","source":"who.int"},{"medicine_name":"vancomycin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","indication":"Endophthalmitis","combined_with":"ceftazidime","status":"Added","atc_classification":"J01XA01","source":"who.int"},{"medicine_name":"vancomycin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","indication":"Endophthalmitis","combined_with":"ceftriaxone","status":"Added","atc_classification":"J01XA01","source":"who.int"},{"medicine_name":"vancomycin","eml_section":"Watch group antibiotics","formulations":"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","indication":"Methicillin resistant Staphylococcus aureus","combined_with":null,"status":"Removed","atc_classification":"J01XA01","source":"who.int"},{"medicine_name":"varenicline","eml_section":"Medicines for nicotine use disorders","formulations":"Oral > Solid: 0.5 mg; 1 mg","indication":"Nicotine dependence","combined_with":null,"status":"Added","atc_classification":"N07BA03","source":"who.int"},{"medicine_name":"varicella vaccine","eml_section":"Recommendations for immunization programmes with certain characteristics","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BK01","source":"who.int"},{"medicine_name":"vecuronium","eml_section":"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","formulations":"Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)","indication":"Muscle relaxants","combined_with":null,"status":"Added","atc_classification":"M03AC03","source":"who.int"},{"medicine_name":"vemurafenib","eml_section":"Targeted therapies","formulations":null,"indication":"Other specified melanoma of skin","combined_with":null,"status":"Removed","atc_classification":"nan","source":"who.int"},{"medicine_name":"verapamil","eml_section":"Antiarrhythmic medicines","formulations":"Parenteral > General injections > IV: 2.5 mg per  mL in 2 mL ampoule (hydrochloride)\nOral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)","indication":"Supraventricular tachyarrhythmia","combined_with":null,"status":"Added","atc_classification":"C08DA01","source":"who.int"},{"medicine_name":"verapamil","eml_section":"Antianginal medicines","formulations":"Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)","indication":"Angina pectoris","combined_with":null,"status":"Added","atc_classification":"C08DA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Kaposi sarcoma of unspecified primary site","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Other specified malignant neoplasms of the ovary","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Germ cell tumour of testis","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Anaplastic large cell lymphoma, ALK-negative","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Anaplastic large cell lymphoma, ALK-positive","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vinblastine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)\nParenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"L01CA01","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Unspecified malignant neoplasms of ill-defined or unspecified sites","combined_with":null,"status":"Removed","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Other specified gliomas of brain","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Malignant trophoblastic neoplasms of placenta","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Follicular lymphoma","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Kaposi sarcoma of unspecified primary site","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Hodgkin lymphoma","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Diffuse large B-cell lymphomas","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Retinoblastoma","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Burkitt lymphoma including Burkitt leukaemia","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Malignant neoplasms of kidney, except renal pelvis","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Ewing sarcoma of bone and articular cartilage of unspecified sites","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Lymphoid leukaemia, not elsewhere classified","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vincristine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)\nParenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","indication":"Langerhans cell histiocytosis","combined_with":null,"status":"Added","atc_classification":"L01CA02","source":"who.int"},{"medicine_name":"vinorelbine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial\nParenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial\nOral > Solid: 20 mg; 30 mg; 80 mg","indication":"Other specified malignant neoplasms of bronchus or lung","combined_with":null,"status":"Added","atc_classification":"L01CA04","source":"who.int"},{"medicine_name":"vinorelbine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial\nParenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial\nOral > Solid: 20 mg; 30 mg; 80 mg","indication":"Other specified malignant neoplasms of breast","combined_with":null,"status":"Added","atc_classification":"L01CA04","source":"who.int"},{"medicine_name":"vinorelbine","eml_section":"Cytotoxic medicines","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial\nParenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial\nOral > Solid: 20 mg; 30 mg; 80 mg","indication":"Rhabdomyosarcoma primary site","combined_with":null,"status":"Added","atc_classification":"L01CA04","source":"who.int"},{"medicine_name":"voriconazole","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 200 mg in vial powder for injection\nOral > Liquid: 40 mg per  mL powder for oral liquid\nOral > Solid: 50 mg tablet; 200 mg tablet","indication":"Chronic pulmonary aspergillosis","combined_with":null,"status":"Added","atc_classification":"J02AC03","source":"who.int"},{"medicine_name":"voriconazole","eml_section":"Antifungal medicines","formulations":"Parenteral > General injections > IV: 200 mg in vial powder for injection\nOral > Liquid: 40 mg per  mL powder for oral liquid\nOral > Solid: 50 mg tablet; 200 mg tablet","indication":"Invasive aspergillosis","combined_with":null,"status":"Added","atc_classification":"J02AC03","source":"who.int"},{"medicine_name":"warfarin","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","indication":"Other specified diseases of arteries or arterioles","combined_with":null,"status":"Added","atc_classification":"B01AA03","source":"who.int"},{"medicine_name":"warfarin","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","indication":"Cerebral ischaemic stroke due to embolic occlusion","combined_with":null,"status":"Added","atc_classification":"B01AA03","source":"who.int"},{"medicine_name":"warfarin","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","indication":"Venous thromboembolism","combined_with":null,"status":"Added","atc_classification":"B01AA03","source":"who.int"},{"medicine_name":"warfarin","eml_section":"Medicines affecting coagulation","formulations":"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","indication":"Atrial fibrillation","combined_with":null,"status":"Added","atc_classification":"B01AA03","source":"who.int"},{"medicine_name":"water for injection","eml_section":"Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous","formulations":"Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule","indication":"Unspecified appropriateness of dosing or administration without injury or harm","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"whole blood","eml_section":"Blood and blood components","formulations":"Parenteral > General injections > IV: ","indication":"Blood transfusion without reported diagnosis","combined_with":null,"status":"Added","atc_classification":"nan","source":"who.int"},{"medicine_name":"xylometazoline","eml_section":"Ear, nose and throat medicines [c]","formulations":"Local > Nasal > Spray: 0.05% w\/v equivalent to 0.5 mg per mL","indication":"Nasal congestion","combined_with":null,"status":"Added","atc_classification":"R01AA07","source":"who.int"},{"medicine_name":"yellow fever vaccine","eml_section":"Recommendations for certain regions","formulations":"All vaccines should comply with the WHO requirements for biological substances.","indication":"Need for immunization against certain single viral diseases","combined_with":null,"status":"Added","atc_classification":"J07BL01","source":"who.int"},{"medicine_name":"zanubrutinib","eml_section":"Targeted therapies","formulations":"Oral > Solid: 80 mg","indication":"Mantle cell lymphoma","combined_with":null,"status":"Removed","atc_classification":"L01EL03","source":"who.int"},{"medicine_name":"zidovudine","eml_section":"Antiretrovirals > Nucleoside\/Nucleotide reverse transcriptase inhibitors","formulations":"Parenteral > General injections > IV: 10 mg per  mL in 20 mL vial solution for IV infusion injection\nOral > Liquid: 50 mg per 5 mL\nOral > Solid: 250 mg capsule; 300 mg tablet","indication":"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","combined_with":null,"status":"Added","atc_classification":"J05AF01","source":"who.int"},{"medicine_name":"zinc sulfate","eml_section":"Medicines for diarrhoea","formulations":"Oral > Solid: 20 mg","indication":"Diarrhoea","combined_with":null,"status":"Added","atc_classification":"A12CB01","source":"who.int"},{"medicine_name":"zoledronic acid","eml_section":"Supportive medicines","formulations":"Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle","indication":"Malignant neoplasm metastasis in bone or bone marrow","combined_with":null,"status":"Added","atc_classification":"M05BA08","source":"who.int"}]